

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

### Risk of infections among persons treated with opioids for chronic pain: A systematic review and meta-analysis protocol.

Journal:	BMJ Open
Manuscript ID	bmjopen-2023-083791
Article Type:	Protocol
Date Submitted by the Author:	29-Dec-2023
Complete List of Authors:	Kudrina, Irina; McGill University Montreal, Family Medicine Department; Research Institute McGill University Health Center Page, G; Université de Montréal, Anesthesiology and Pain Medicine Choinière, Manon; Centre hospitalier de l'Université de Montréal (CHUM) Research Center; Université de Montréal, Department of Anesthesiology Shir, Yoram; McGill University, Anesthesia Eisenberg, Mark; McGill University, Cardiology; Lady Davis Institute for Medical Research Centre for Clinical Epidemiology Ben-Sasson, Maayan; McGill University Faculty of Medicine and Health Sciences Lebouché, Bertrand; McGill University Faculty of Medicine and Health Sciences, Chronic Viral Illness Service, McGill University Health Centre; McGill University Faculty of Medicine and Health Sciences, Department of Family Medicine, McGill University Puzhko, Svetlana; University Bielefeld, Department of General Practice and Family Medicine
Keywords:	INFECTIOUS DISEASES, IMMUNOLOGY, PAIN MANAGEMENT, Meta- Analysis, Systematic Review

# SCHOLARONE<sup>™</sup> Manuscripts

1 2		
3 4	1	Risk of infections among persons treated with opioids for chronic pain: A systematic
5	2	review and meta-analysis protocol.
6 7	3	
8 9	4	Irina Kudrina, <sup>1,2,3,4</sup> M. Gabrielle Pagé, <sup>5</sup> Manon Choinière, <sup>5</sup> Yoram Shir, <sup>2</sup> Mark J. Eisenberg, <sup>6</sup>
10 11	5	Maayan BenSasoon, <sup>2</sup> Bertrand Lebouché, <sup>1,3,7</sup> Svetlana Puzhko <sup>8</sup>
12 13	6	Author affiliations
14	7	<sup>1</sup> Faculty of Medicine and Health Sciences, Family Medicine Department, McGill University,
15 16	8	Montreal, Quebec, Canada
17 18	9	<sup>2</sup> Alan Edwards Pain Management Unit, Anesthesia Department, Faculty of Medicine and Health
19 20	10	Sciences, McGill University, Montreal, Quebec, Canada
21	11	<sup>3</sup> Division of Secondary Care, Faculty of Medicine and Health Sciences, McGill University
22 23	12	<sup>4</sup> BRAiN& neurosciences, Research Institute, McGill University Health Center, Montreal, Quebec,
24 25	13	Canada
26 27	14	<sup>5</sup> Department of Anesthesiology and Pain Medicine, Faculty of Medicine, Université de
28	15	Montréal, Montreal, Quebec, Canada
29 30	16	Research center, Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada
31 32	17	<sup>6</sup> Center for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General
33 34	18	Hospital, Montreal, QC, Canada
35	19	Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada
36 37	20	Departments of Epidemiology, Biostatistics and Occupational Health, McGill University,
38 39	21	Montreal, QC, Canada
40 41	22	Division of Cardiology, Jewish General Hospital, McGill University, Montreal, QC,
42	23	<sup>7</sup> Centre for Outcomes Research & Evaluation, Research Institute of the McGill University
43 44	24	Health Centre, Montreal, Quebec, Canada
45 46	25	Chronic Viral Illness Service, Division of Infectious Disease, Department of Medicine, McGill
47 48	26	University Health Centre, Montreal, Quebec, Canada
49	27	<sup>8</sup> Department of General Practice and Family Medicine, University of Bielefeld, Germany
50 51	28	
52 53	29	Corresponding author: Irina Kudrina, Alan Edwards Pain Management Unit, McGill University
54	30	Health Center. 1650 ave. Cedar, Montreal General Hospital, Montreal, Quebec, Canada H3G1A4
55 56	31	Email: Irina.kudrina@mcgill.ca
57 58		1
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

## 32 ABSTRACT

> Millions of persons with chronic pain across North American and European countries use opioids. Immunosuppressive properties of opioids and associated risks of infections result in avoidable morbidity and mortality.

Methods and Analysis. Methodology is based on the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses statement, the MOOSE Guidelines for Meta-Analyses and
Systematic Reviews of Observational Studies, and the Cochrane Handbook for Systematic
Review of Interventions. We plan to systematically search Ovid MEDLINE, CINAHL,
PsycINFO, EMB Review, EMBASE, Cochrane Database of Systematic Reviews, Cochrane
Central Register of Controlled Trials, and Google Scholar databases from the inception date to
December 2023. Primary studies full text (in English, French, Spanish, Hebrew, and German)
reporting measurable outcomes in adults with chronic pain, all routes of opioid use, all types of
infections and all settings will be included. We will identify a scope of reported infections, and
the evidence on the association of opioid use (including specific opioid, dosage, formulation, and
duration of use) with the risk of negative infectious outcomes. Opioid use-associated outcomes,
comparing opioid use to another opioid or a non-opioid medication will be reported. Metaanalysis will incorporate individual risk factors. If data are insufficient, results will be
synthesized narratively. Publication bias and confounding evaluation will be performed. The
GRADE framework will be used.

Ethics and Dissemination. Approval for the use of published data is not required. Results will be
published, presented at conferences, and discussed in deliberative dialogue groups.

## 56 STRENGTHS AND LIMITATIONS OF THIS STUDY

- First-of-its-kind extensive comprehensive systematic review planned on the topic
- Inclusion of all types of opioids, doses, duration, and routes of administrations (except illicit self-injection)
- Multi-database and multi-lingual systematic search
  - Limited to quantitative studies reporting measurable outcomes only

#### **BMJ** Open

• We will not search for all specific infectious agents separately, which will probably result in
missing some pertinent studies

#### 66 INTRODUCTION

The COVID-19 pandemic brought to light synergistic public health crises of poorly managed chronic pain (CP) (1) and rising opioid prescribing rates (2, 3) culminating in increased prevalence of opioid use associated complications like acute overdoses or chronic hormonal and immune disturbances (4-6). CP, defined as pain lasting more than three months (7), is common worldwide, affecting 18% of the population across developing nations (8) to more than 20% of population in the U.S. and Canada (7). About 11% of young adults (9) and up to 85% of elderly patients (10) live with CP, including pain-related disability (11, 12) frequently associated with opioid use. Reportedly, the direct and indirect costs to society from pain and opioid crises pre-pandemic in Canada ranged anywhere from \$38.3 to \$40.4 billion annually (13). 

The prevalence of opioid use in Canada is estimated more than 12% of the population (14), making Canada one of the leading opioid consumers in the world (988 mg morphine equivalent per 1000 inhabitants/day), with similar trends observed across the United States and European countries like Germany (15) and Netherlands (16). With age, the proportion of patients with CP using licit and illicit opioids increases (17), and so does the prevalence of opioid-related fatal and non-fatal adverse effects. In 2022 alone, the Canadian government reported ~20 opioid-related deaths and hundreds of hospitalizations daily (18). These statistics, however, do not include a much higher prevalence of opioid use associated long-term sequela. 

*Multimorbidity* (19) and low socio-economic status (SES) are linked with CP (20) and opioid use, confounding the development of immunosuppression and poor health (21, 22) (Figure 1). CP disproportionately affects persons from marginalized (racialized, poor etc.) communities and the elderly (10, 23). As the World Health Organization pointed, "… health and illness follow a social gradient: the lower the socioeconomic position, the worse the health" (24). Furthermore, an overall link between multimorbidity, polypharmacy, neuro-immune disturbances and infections appears well established (25). Several common chronic disease states like metabolic syndrome,

BMJ Open: first published as 10.1136/bmjopen-2023-083791 on 15 October 2024. Downloaded from http://bmjopen.bmj.com/ on June 8, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

inflammatory arthritis, major depression, various pain syndromes, prolonged stress, and posttraumatic stress disorder (26-28) are associated with long-term disturbances of the hypothalamicpituitary-adrenal (HPA) axis, pro-inflammatory (e.g., cytokine-driven) systemic changes (26, 27),
and various degrees of immunosuppression. Unsurprisingly, the risk of negative infectious
outcomes in these persons is reportedly higher than in general population (29-33). Thus, the use
of immunosuppressive analgesics like opioids becomes a careful balancing act against their
potential capacity to further suppress HPA-immune axes.

Our knowledge of opioid-associated infections is not new (34-37). Among others, illicit injecting practices have been linked to an array of blood born infections like HIV, osteomyelitis, skin and epidural abscesses, and infective endocarditis (37-40). In the States (2002-2012), hospitalizations related to opioids and opioid-associated infections cost American Medicaid \$15 billion and \$700 million respectively (37). In Canadian Ontario (41), a significant increase in the rates of infective endocarditis (167%), spinal infections (394%), skin and soft tissue infections (147%) is also reported (2013-2019). The ten highest burden pathogens of interest (S. pneumoniae, Escherichia coli, Human Papillomavirus, Hepatitis B virus, HIV, HCV, Staphylococcus aureus, influenza virus, Clostridium difficile, rhinovirus) have accounted for >65% of health-adjusted life years lost due to premature morbidity and mortality (42). It is estimated that only antimicrobial-resistant (43) and hospital-acquired (44) infections cost Canadians additional \$3.5 billion a year. 

The importance of the confluent effect of the opioid-induced immunosuppression and the risk of infections is difficult to overestimate. There is an already good understanding (45, 46) of the effectiveness of the HIV and hepatitis C infections prevention strategies in persons who inject illicit opioids. In pain however, the CDC (11, 47), Canadian (48), and European (49, 50) pain and opioid prescribing guidelines although acknowledge the possibility of endocrine and immune disturbances, yet do not offer any guidance on balancing opioid use and risk of infections in these populations. No consensus has been reached regarding the risk of specific opioids and no corresponding prevention strategies have been identified. 

*Opioid use for CP* presents a spectrum ranging from a sub-group of patients taking occasional 123 small doses of opioids, to patients treated with regular medium-to-high-dose opioid therapy, and Page 5 of 26

#### **BMJ** Open

all the way to another sub-group of patients who live with concomitant CP and opioid use disorder. It is estimated that >20% of patients with musculoskeletal CP overconsume or misuse opioids, and 15% live with opioid use disorder (51). Similarly, in a SR of 15 studies (52) looking at cancer-related CP, opioid misuse was reported being as high as 27.8%, and opioid use disorder ranged up to 20%. The data thus converge to demonstrate that although most patients with CP do not engage in risky behaviours, therapeutic and recreational uses might not always be easily separable. Many patients diagnosed with opioid misuse or use disorders, had their first exposure to an opioid in the context of CP diagnoses (53-55). More so, persistent opioid use could also develop post-acute trauma and surgery (56), leading to chronic opioid toxicity and its sequela. 

Opioids belong to a diverse class of molecules, including natural ones like opium, morphine and codeine, their derivatives (e.g., heroin, hydromorphone, oxycodone) and synthetic ones (buprenorphine, tramadol, fentanyl etc.) They exert therapeutic and non-therapeutic effects via opioid receptors of the endogenous opioid system (4, 57), one of the most omnipresent neuro-transmitter systems in the mammalian organism closely involved in analgesia, stress and immune responses (4-6, 26, 58). It was shown that the mu-opioid receptors are found on immune cells like macrophages (59), T and B lymphocytes (60, 61), natural killer (62), and even glial cells (63) that provide support and protection for the neurons. Notably, opioid-induced glial changes are thought to be implicated in the development of opioid-induced hyperalgesia (abnormally increased pain) (64), a phenomenon that can drive prolonged opioid use and dose escalation. Aside from the dose and duration, immunosuppressive effects and risk of infections likely vary by specific opioid (6, 65). 

41 146

*Clinical immunosuppression* in acute post-operative settings (e.g., abdominal surgeries) with the use of remifentanil anesthesia is associated with higher infection rates at the surgical sites when compared with fentanyl (66). Buprenorphine appears to be one of the safest options (67, 68), and long-acting opioid formulations are associated with a greater HPA axis suppression (69, 70) and a higher risk of infectious complications (71, 72) than short-acting opioids. Thus, some authors categorize opioids into "more immunosuppressive" (e.g., morphine, fentanyl, codeine, dihydrocodeine, methadone) "less and immunosuppressive" (oxycodone, tramadol, 

buprenorphine, hydromorphone) (73-78), although this classification lacks systematic evidence support and is not widely accepted. 

*Preliminary data in CP*. Despite variations in methodological approaches (79), the trends across primary studies have been pointing to the same direction. A non-systematic biophysiological review (22) laid much support to the hypothesis that opioids in general, and especially long-term opioid therapy (> 3 months), can alter parameters of the innate and adaptive immunity in patients with CP in a clinically meaningful way. A preliminary search (August 15, 2023) of the Medline Ovid and Google Scholar databases in English revealed a sample of primary and synthesis studies on the topic (1, 22, 80-86) (71, 72, 87-98), analyzing the association with serious infections (pneumonia, bacteremia, sepsis, meningitis/encephalitis, septic arthritis/osteomyelitis, endocarditis, pyelonephritis, and cellulitis), and corresponding rates of hospitalizations, ICU admissions, and mortality. Thus, given the scope and severity of the converging public health crises and sufficient literature published to date, there is a critical need for systematically synthesized knowledge on the risk of opioid therapy and associated infectious in persons with CP using opioids, outside of the illicit self-injecting practices. To our knowledge, this SR will be the first one on the topic. It will contribute to informing clinical practice guidelines, opioid prescribing policies, and clinical practices across Canada and internationally. 

#### **Registration.**

The protocol was registered in PROSPERO on 18 March 2023 (CRD42023402812) 

#### **REVIEW QUESTIONS AND OBJECTIVES**

#### **Review questions**

The overarching review question for this SR is: What is the evidence on the association of opioid use with increased risks for infections, re-infections, and negative infectious outcomes among persons with chronic pain using opioids (excluding illicit self-injecting practices)? 

The secondary review question is: Does the association between the use of opioids and risks for infectious outcomes depend on the specific opioid, dosage, formulation, and duration of use? 

1 2		
- 3 4	183	
5 6 7 8 9 10 11	184	Objectives
	185	Primary objectives are to:
	186	1. Identify the scope of infections in opioid users (IPO) as described in studies selected for this
	187	systematic review.
12	188	2. Synthesize the evidence on the difference in the infection acquisition risks between persons with
13 14 15 16	189	CP who use opioids versus a comparator as available in the literature.
	190	3. Synthesize the evidence on the difference in IPO-related outcomes (i.e., hospitalizations,
17	191	duration of hospital stays, intensive care unit (ICU) admissions, mortality, etc.) between persons
18 19	192	with CP who use opioids versus a comparator.
20 21	193	Secondary objectives (data permitting) are to:
22 23	194	1. Examine if the risk for negative <i>IPO</i> -related outcomes is associated with the opioid dose, opioid
24	195	formulation (long- vs short-acting) and duration of use.
25 26	196	2. Identify opioids associated with a higher risk of infection acquisition and/or negative IPO-
27 28	197	related outcomes.
29 30	198	3. Identify specific individual-level characteristics that may be associated with an increased risk
31 32 33 34 35 36 37 38 39	199	of infection acquisition and/or negative IPO-related outcomes.
	200	
	201	METHODS AND ANALYSIS
	202	The SR methodology is based on the MOOSE Guidelines for Meta-Analyses and Systematic
	203	Reviews of Observational Studies (99), and the Cochrane Handbook for Systematic Review of
40 41	204	Interventions (100). The results will be reported according to the Preferred Reporting Items for
42 43	205	Systematic Reviews and Meta-Analyses (PRISMA) statement (101). This protocol was registered
44 45	206	in PROSPERO, and important protocol amendments will be documented in PROSPERO.
46 47	207	Operational definitions
48 49	208	1) CP includes cancer pain, cancer treatment-induced pain, and non-cancer pain (7, 102).
50	209	2) Opioids are substances exerting their physiologic effects via opioid receptors. All opioids and
51 52	210	their formulations will be included in this SR.
53 54	211	3) IPO include all (bacterial, viral, and fungal) infections described in studies selected for this SR.
55 56		
57 58		7
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

4) All routes of administration (oral, transdermal, intravenous, intra-thecal, etc.) will be included. Due to the potential risk of shared needle/syringe contamination unrelated to immunosuppressive properties of studied medicines, we will exclude illicit self-injection of opioids. 5) Opioid use of various duration will be considered, including *acute/short term* (< 12 weeks) and *chronic* ( $\geq$  12 weeks) opioid use. 6) *Type of opioid use* will be categorized as *episodic* (total days of opioid supply <90 in 3 months or documented non-daily use) or *continuous* (total days of opioid supply  $\ge 90$  in 3 months or documented daily use). 7) Outcomes include infection acquisition rates, infections-related hospitalizations, duration of hospital stays, ICU admissions, and mortality. 8) Dose reporting. Whenever possible, we will convert and report morphine equivalent daily doses (MEDD) (47, 48). **Eligibility criteria** Eligibility criteria will be defined based on the PECO approach. Participants are patients with CP who use opioids, and who do not self-inject illegal/recreational opioids. *Exposure* is all opioid use, except illegal self-injection of opioids. *Comparator* is a population from the same setting (ICU, for example) using another opioid or a non-opioid medication. *Outcome* is the scope of the *IPO* and measurable infection-related outcomes (see Outcome reporting) (103). We will include all relevant primary studies reporting all routes of opioid use by adult humans, all infections (including COVID-19) during opioid use period, and all settings. We will include full texts (in English, French, Spanish, Hebrew and German) reporting measurable outcomes and various designs (randomized and non-randomized trials, observational studies, case series, and mixed methods studies (quantitative portion)). Studies focusing on pediatric populations, palliative/end-of-life care, self-injection of illegal/recreational opioids, qualitative designs, opinions, commentary, abstracts, conference proceedings will be excluded. Search strategy Databases. An experienced medical liaison McGill librarian will be involved. We plan to systematically search Ovid MEDLINE, CINAHL, PsycINFO, EMB Review, EMBASE, Cochrane 

58

59

60

#### **BMJ** Open

BMJ Open: first published as 10.1136/bmjopen-2023-083791 on 15 October 2024. Downloaded from http://bmjopen.bmj.com/ on June 8, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

2							
3 4	243	Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, and Google					
5	244	Scholar databases from the inception date to December 2023 using a combination of medical					
6 7	245	subject headings (MeSH) and keywords. Grey literature: (Pro Quest, Dissertation and Theses;					
8 9	246	published reports) will be searched. The Keywords and MeSH terms will be entered for the					
10	247	concepts: "opioids", "infections", and "pain" using Boolean operator AND for: (1) all commonly					
11 12	248	used opioids (generic, brand names, and synonyms); (2) infections (all viral, bacterial, and other					
13 14	249	infections); and (3) pain (cancer, non-cancer). The search strategy will be adopted to each database					
15 16	250	(see example in Table 1.) Backward and forward citation searches will be performed					
17	251						
18 19		Table 1       Example search strategy (Medline via Ovid)					
19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45		<ul> <li>Description         <ul> <li>(exp analgesics, opioid/ or exp opioid-related disorders/or (narcotic* or opiate* or opioid* or bezitramide or anapce or ardinex or asimadolin* or astramorph or avinza or or acetylmethadol or alfentanil or anileridine or Belladonna or Benzomorphan* biodalgic or bpethidine or buprenorphine or carfentanil or codeine or codinovo or contramal or demerol or dicodid or dihydrocodeinone or dihydrohydroxycodeinone or dihydromorphinone or dihydrone or dilaudia or dinarkon or dolarin or dolargan or dolcontral or dolosal or dur?gesic or dur?morph or epimorph or eucodal or exalgo or fentanest or fentanyl or fentora or fortral or heroin or hycodan or hycoro and r hydrocodeinonebitatrate or hydrocodone or hydrocodone* or hydromorphon or hydromorphon or hydroxyacetanilide or hydroxydoeinon or hysingla or isocodeine or isonipecain or jutadol or kadian or 1 dromoran or laudacon or levodromoran or levodromoran or levorphan or levorphan or levir or lidol or lorcet or lortab or lydol or meperidine hydrochloride or methadone or morfin or morfine or morphin or morphinum or morphinum or mos contin or n methylmorphine or nacrocic or n-methylmorphine or nable or oxiscedone or skenan or oxycodoen or oxycone or oxycontin or oxymorphone or palladone or pancodine or patazocine or percocet or pethidine or phentanyl or prontofort or propoxyphene or robidone or tramadol or tramadol or tramadolor or tramadorsch or tramadura or tramagetic or tramadur or tramade or tramadol or tramadol or tramadorsch or tramadura or tramagetic or tramadur or tramade or tramado or zydol or zytram).tw, sh, kw, kf, oa, nm</li> <li>2 (Infections[Mesh] OR Infect*[tw] OR chronic Pain[tw] OR Cancer Pain[tw] OR Pain Management[tw])</li> <li><b>4</b> #1 AND #2 AND #3</li> <li>Filters: in the last 10 years, Humans, English, French, German, Hebrew, Spanish Adult: 19+ years</li> </ul></li></ul>					
46 47	252						
48	253	Study selection					
49 50	254	The Covidence systematic review software (104) will be used to perform screening, quality					
51 52	255	assessment and data extraction, and to document decisions on inclusion/exclusion. First, two					
53	256	independent reviewers will screen manuscripts by titles and abstracts. We will calculate kappa-					
54 55 56 57	257	statistic (inter-rater agreement) to ensure consistency of the selection process (105, 106). Before					

BMJ Open: first published as 10.1136/bmjopen-2023-083791 on 15 October 2024. Downloaded from http://bmjopen.bmj.com/ on June 8, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

screening, a stepwise calibration test will be performed on a sample of 30 studies, with the aim of achieving 80% agreement between reviewers. We will report changes to the inclusion and exclusion criteria that result from the calibration as deviations from the published protocol. All potentially relevant studies will be carried forward at each step. The remaining full texts will be reviewed for eligibility independently by two researchers. Disagreements will be resolved by consensus with a third reviewer.

#### 265 Data extraction

To extract the data, we will adopt a modified Effective Practice and Organisation of Care (EPOC) Cochrane Data Collection forms (100, 107). The extracted data will be categorized into: 1) the patients' characteristics (sex at birth, gender, age, sociodemographic, psychosocial, and available medical characteristics (immunosuppression, number of co-morbidities); 2) opioid use status (continuous, episodic or no use, opioid formulation, opioid type and dose); 3) infection-related factors, such as infection diagnosis (e.g., pneumonia), infection type (bacterial, viral, fungal) and, if available, specific infectious agent (e.g., *Clostridium*); 4) clinical settings (e.g., community, hospital, intensive care unit); and 5) clinical disciplines (e.g., orthopedic surgery) and 6) measurable outcomes (e.g., duration of hospital stays; intensive care unit admissions) and severity (requiring intubation, mechanical ventilation, sepsis, septic shock, mortality). One researcher will extract the data and another researcher will check the extracted data for errors and plausibility. 

#### **Outcome reporting**

For *primary objective 1*, all infections reported in quantitative studies will be documented, and relevant details on the population, settings, and opioid use will be described. For *primary objective* 2, we will synthesize the evidence on the differences of infection acquisition risks between persons who use opioids versus a comparator. For *primary objective 3*, we will synthesize the evidence on the differences in *IPO*-related measurable outcomes (e.g., duration of hospital stays) and severity (e.g., septic shock) between persons who use opioids versus comparator. For primary objectives 2 and 3, meta-analysis of the extracted effect measures will be performed; pooled effect measures will be reported (if feasible). 

For *secondary objective* 1, if data allow, we will synthesize the evidence on the relationships
between the opioid dose, duration of use, opioid formulation (long- vs short-acting) and reported

#### **BMJ** Open

*IPO* outcomes. For *secondary objective 2*, if data allow, we will identify specific opioids that are
associated with a higher risk of infection acquisition and poor outcomes. If data allow, for *secondary objective 3*, we will identify individual risk factors (e.g., age, gender, ethnicity,
comorbidities) that are associated with a higher risk of infection acquisition and poor outcomes.
Tabulated data and qualitative descriptions will be provided for secondary objectives 1, 2 and 3.

**Risk of bias in individual studies** 

We will review included articles and assess the risk of bias for each outcome of interest. Disagreements will be discussed until a consensus is reached. In case of unresolved disagreement, a third reviewer will be invited to appraise the study. We will employ a validated EPHPP (Canadian Effective Public Healthcare Panacea Project) Quality Assessment Tool (108) based on eight categories universally applicable to quantitative studies that has a good inter- and intra-rater reliability (109, 110). The EPHPP tool is widely cited and was chosen for its excellent properties in evaluating studies in the pain field (110). We will record the study's funding sources and authors' conflicts of interest statements. 

#### **305 Data synthesis**

The PRISMA flowchart (111, 112) will be used to describe the study selection process. We will tabulate the data on included studies and their populations, the identified risk factors, and the outcome characteristics, using frequency counts. All measurable outcomes extracted from the included studies will be used in data synthesis. If two or more studies for a specific measurable outcome are available, we will perform meta-analysis using the Review Manager (RevMan) software (113). Standardized mean difference with 95% CI for continuous outcomes, and odds ratios, relative risk ratios or hazard ratios with 95% CI for dichotomous outcomes will be used in meta-analysis. Whenever possible, we will transform other effect estimates into these effect measures. Higgins' I<sup>2</sup> statistics (100, 114) (i.e., the percentage of variability in the effect size estimates due to heterogeneity) will be calculated. Based on our pilot search, we anticipate some data heterogeneity, which will require the use of a random-effect model to calculate the pooled effect sizes. If sufficient data on the adjusted effect measures are available, we will calculate both pooled adjusted and crude effect sizes (see sensitivity analysis). If the information on the specific opioids-related (opioid dose, opioid formulation, treatment duration) and individual-level 

characteristics are available, we will conduct subgroup analysis and will report group-specific
effect estimates. The results of meta-analysis will be presented as forest plots. If data are
insufficient to conduct meta-analysis for one of the objectives, we will use a narrative approach to
data synthesis.

325 SGBA+ analysis

Integrating sex and gender is of crucial importance to our study as both variables exhibit multi-directional effects and can be confounders or effect modifiers (see Figure 1). We will apply a broad theoretical and empirical framework to understand the development of IPOs and underlying mechanisms, integrating up-to-date sex and gender, pain, and addiction literature. Thus, rather than focusing on the artificially binary categories such as man/woman (for gender) or male/female (for sex), we will take the real-life complexity of these characteristics into consideration. The following categories will be reflected in our data extraction sheet: sex assigned at birth (Female, Male, Intersex) and gender identity (Woman, Man, Transgender, Gender fluid or Gender nonbinary, Two-Spirit (Indigenous), and Other). The authors of primary studies will be contacted to obtain missing data on non-binary sex and gender categories, and their responses will be thoroughly documented. We will stratify our analysis by sex /gender categories and will report sex or gender-specific effect measures separately. We will ensure inclusion of sex and gender-specific effect measure estimates in the discussion, as well as the issue of missing non-binary data. 

36 339

#### 340 Publication bias, confounding, sensitivity analysis and quality of cumulative evidence

*Publication bias* will be assessed examining funnel plots for each outcome, for which more than
342 10 studies were included in the meta-analysis (100).

43 343

*Confounding*. Sex/gender, history of opioid use, the use of other immunosuppressive medications etc. may have confounding of effect modifying effects in the association between opioid use and risk for infectious outcomes (see Fig. 1). As our pilot search showed, most studies are of observational design, and thus may be prone to the confounding by indication bias. For example, it may seem that patients prescribed opioids are likely to have a more severe disease than persons not prescribed opioids, and the more severe disease may be an independent risk for infections. Indeed, this scenario is possible, but not unique. a disease severity is not always reflective of the Page 13 of 26

#### **BMJ** Open

analgesia requirements. For example, when compared to controls, patients who sustained small burns and those with the largest burn surfaces, were respectively 1.73 (95% CI, 1.20 - 2.49) and 1.02 (95% CI, 0.71–1.46) times more likely (98) receive opioids. From our clinical experience and the literature, the decision to prescribe opioids is multi-fold. Thus, most public insurances in Canada cover opioid therapy and frequently do not cover non-pharmacological treatments for CP. This makes opioids an ultimate choice for the poor, not working (e.g., students, elderly) and marginalised populations in Canada. Furthermore, the initial doses in opioid-naïve patients will be lower than among patients taking opioids chronically. Moreover, there is an increasing emphasis in anesthesia protocols to reduce reliance on opioid analgesics (115, 116). In addition, CP literature identifies depression (117, 118), anxiety, and catastrophizing (119) as drivers of opioid dose escalation and chronicity of use. A history of sexual abuse in men, patients' family and personal history of other substance misuse/use disorders are the known risk factors (120) for the problematic opioid use in the future. The attempts to account for the complexity and known confounders, effect modifiers, and important covariates will be made in the analysis. In case these data will be missing from the primary studies, the authors will be contacted. If sufficient data on the important covariates are identified, a subgroup analysis will be conducted, and the subgroup-specific effect estimates will be reported. Epidemiologic biases that can lead to over-/under-estimations of effect sizes or spurious associations will be discussed as study limitations.

Sensitivity analysis. To assess the robustness of our results on each outcome of interest, we will perform sensitivity analyses. First, the pooled effect size estimation will be repeated by including only studies with a low risk of bias, and the results will be compared with the main analysis. Second, we will compare the pooled effect estimates from RCTs and the observational studies. Then, we will evaluate the possible effect of covariates included in the calculation of adjusted effect sizes in original studies on the pooled effect size. For this, we will estimate the pooled crude effect size for each outcome of interest using crude (non-adjusted) effect sizes for separate studies, if available. The effect estimates will be compared with the adjusted effect estimates obtained in the main analysis. 

380	The Grading of Recommendations Assessment, Development and Evaluation (GRADE) (12	21)
381	framework will be used for the assessment of the quality of cumulative evidence for each outco	me
382	of interest. A certainty rating (very low, low, moderate, or high) will be assigned.	
383		
384	PATIENT AND PUBLIC INVOLVEMENT	
385	This manuscript is a protocol for SR. As SR results are available, we will organize downstre	am
386	deliberative dialogue groups with patients, care providers and decision makers to develop the m	ost
387	optimal ways for knowledge uptake and implementation across clinical settings in Canada,	the
388	United States, Israel, Germany and other European countries.	
389		
390	ETHICS and DISSEMINATION	
391	This review is based on already published literature thus, no ethics review was requested. Resu	ults
392	will be published, presented at conferences, and discussed in deliberative dialogue groups.	
393		
394	Timeline for review	
395	At the time of submission, we had already started database searches.	
396		
397	AUTHORS CONTRIBUTIONS	
398	Irina Kudrina: Conceptualization, writing original draft, methodology, review and editing.	
399	Gaberielle Pagé: methodology, review and editing.	
400	Manon Choinière: methodology, review and editing.	
401	Yoram Shir: review and editing.	
402	Maayan BenSasoon: review and editing.	
403	Bertrand Lebouché: review and editing.	
404	Mark J. Eisenberg: review and editing.	
405	Svetlana Puzhko: Conceptualization, methodology, review and editing.	
406		
407	FUNDING STATEMENT	
408	This research received no specific grant from any funding agency in the public, commercial or	
409	from the not-for-profit sectors.	
410		
		14
	381 382 383 384 385 386 387 388 389 390 391 391 392 393 394 395 396 397 398 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409	381       framework will be used for the assessment of the quality of cumulative evidence for each outco         382       of interest. A certainty rating (very low, low, moderate, or high) will be assigned.         383       PATIENT AND PUBLIC INVOLVEMENT         384       PATIENT AND PUBLIC INVOLVEMENT         385       deliberative dialogue groups with patients, care providers and decision makers to develop the m         386       optimal ways for knowledge uptake and implementation across clinical settings in Canada,         387       United States, Israel, Germany and other European countries.         388       ETHICS and DISSEMINATION         390       ETHICS and DISSEMINATION         391       This review is based on already published literature thus, no ethics review was requested. Rest         392       will be published, presented at conferences, and discussed in deliberative dialogue groups.         393       Timeline for review         394       Timeline for review         395       A t the time of submission, we had already started database searches.         396       Erina Kudrina: Conceptualization, writing original draft, methodology, review and editing.         395       Authors Scontraibutions         396       Irina Kudrina: conceptualization, writing original draft, methodology, review and editing.         397       Maayan BenSasoon: review and editing.

1 2		
2 3 4	411	COMPETING INTERESTS STATEMENT
5	412	Authors of this manuscript declare no conflict of interest and no competing interests.
6 7	413	MGP is supported by the Junior-2 Salary Award from Fonds de recherche du Québec-Santé
8 9	414	(FRQS)
9 10	415	MJE holds a James McGill Professor award from McGill University.
11 12	416	BL is supported by 2 career awards: a Senior Salary Award from Fonds de recherche du
13	417	Québec–Santé (FRQS) (#311200) and the LE 250 (from the Québec Ministry of Health for
14 15	418	researchers in Family Medicine), from the Quebec's Ministry of Health for researchers in Family
16 17		
18	419	Medicine and holds a Canadian Institutes for Health Research, Strategy for Patient-Oriented
19 20	420	Research Mentorship Chair in Innovative Clinical Trials for HIV Care, has received research
21	421	support, consulting fees and speaker fees from ViiV Healthcare, Merck, and Gilead.
22 23	422	
24	423	
25 26	424	REFERENCES
27 28	425	
29	426	1. Ao G, Li A, Wang Y, Li J, Tran C, Chen M, et al. Opioid usage and COVID-19 prognosis: A systematic review
30	427	and meta-analysis. The American Journal of Emergency Medicine. 2022.
31 32	428	2. Canada Go. Restricting the Marketing and Advertising of Opioids 2021 [Available from:
33	429 430	https://www.canada.ca/en/health-canada/services/opioids/responding-canada-opioid-crisis/advertising-opioid- medications.html.
34	430	3. Simha S, Ahmed Y, Brummett CM, Waljee JF, Englesbe MJ, Bicket MC. Impact of the COVID-19 pandemic on
35	432	opioid overdose and other adverse events in the USA and Canada: a systematic review. Reg Anesth Pain Med.
36	433	2023;48(1):37-43.
37	434	4. Feng Y, He X, Yang Y, Chao D, H Lazarus L, Xia Y. Current research on opioid receptor function. Current drug
38 39	435	targets. 2012;13(2):230-46.
39 40	436	5. Wei G, Moss J, Yuan C-S. Opioid-induced immunosuppression: is it centrally mediated or peripherally
41	437 438	mediated? Biochemical pharmacology. 2003;65(11):1761-6. 6. Sun Q, Li Z, Wang Z, Wang Q, Qin F, Pan H, et al. Immunosuppression by opioids: mechanisms of action on
42	438	6. Sun Q, Li Z, Wang Z, Wang Q, Qin F, Pan H, et al. Immunosuppression by opioids: mechanisms of action on innate and adaptive immunity. Biochemical Pharmacology. 2023:115417.
43	440	7. Treede R-D, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, et al. Chronic pain as a symptom or a disease:
44	441	the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11). Pain. 2019;160(1):19-
45	442	27.
46 47	443	8. Sá KN, Moreira L, Baptista AF, Yeng LT, Teixeira MJ, Galhardoni R, et al. Prevalence of chronic pain in
48	444	developing countries: systematic review and meta-analysis. Pain reports. 2019;4(6).
49	445	9. Murray CB, de la Vega R, Murphy LK, Kashikar-Zuck S, Palermo TM. The prevalence of chronic pain in young
50	446 447	adults: a systematic review and meta-analysis. Pain. 2022;163(9):e972-e84.
51	447 448	10. Stompór M, Grodzicki T, Stompór T, Wordliczek J, Dubiel M, Kurowska I. Prevalence of chronic pain, particularly with neuropathic component, and its effect on overall functioning of elderly patients. Medical science
52	449	monitor: international medical journal of experimental and clinical research. 2019;25:2695.
53	450	11. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids
54 55	451	for pain—United States, 2022. MMWR Recommendations and Reports. 2022;71(3):1.
55 56		
57		
58		15
59		

1

60

2 3 452 12. Morris SP, Fawcett G, Brisebois L, Hughes J. A demographic, employment and income profile of Canadians 4 453 with disabilities aged 15 years and over, 2017. Statistics Canada= Statistque Canada; 2018. 5 454 Campbell F, Hudspith M, Choinière M. Working together to better understand, prevent, and manage 13. 6 455 chronic pain: what we heard. A report by the Canadian Pain Task Force. 2020. 7 456 14. Carriere G, Garner R, Sanmartín C. Significant factors associated with problematic use of opioid pain relief 8 457 medications among the household population, Canada, 2018. Health Reports. 2021;32(12):11-26. 9 458 Ju C, Wei L, Man KK, Wang Z, Ma T-T, Chan AY, et al. Global, regional, and national trends in opioid analgesic 15. 10 459 consumption from 2015 to 2019: a longitudinal study. The Lancet Public Health. 2022;7(4):e335-e46. 11 460 Kalkman GA, Kramers C, van Dongen RT, van den Brink W, Schellekens A. Trends in use and misuse of opioids 16. 12 461 in the Netherlands: a retrospective, multi-source database study. The Lancet Public Health. 2019;4(10):e498-e505. 13 462 17. Canada S. Pain relief medication containing opioids, 2018 2018 [Available from: 14 463 https://www150.statcan.gc.ca/n1/pub/82-625-x/2019001/article/00008-eng.htm. 15 464 18. Canada Go. Opioid- and Stimulant-related Harms in Canada Published:(June 2023) 2023 [Available from: 16 465 https://health-infobase.canada.ca/substance-related-harms/opioids-stimulants/. 17 466 Geda NR, Janzen B, Pahwa P. Chronic disease multimorbidity among the Canadian population: prevalence 19. 18 467 and associated lifestyle factors. Archives of Public Health. 2021;79(1):1-11. 19 468 20. Prego-Domínguez J, Khazaeipour Z, Mallah N, Takkouche B. Socioeconomic status and occurrence of chronic 20 469 pain: a meta-analysis. Rheumatology. 2021;60(3):1091-105. 21 Haroutounian S. Postoperative opioids, endocrine changes, and immunosuppression. Pain Reports. 470 21. 22 471 2018;3(2). 23 472 Diasso PD, Birke H, Nielsen SD, Main KM, Højsted J, Sjøgren P, et al. The effects of long-term opioid 22. 24 473 treatment on the immune system in chronic non-cancer pain patients: A systematic review. European Journal of 25 474 Pain. 2020;24(3):481-96. 26 475 23. CDC. Trends and Geographic Patterns in Drug and Synthetic Opioid Overdose Deaths — United States, 27 476 2013-2019 28 29 477 2022. 30 WHO WHO. Social determinants of health 2023 [Available from: https://www.who.int/health-topics/social-478 24. 31 479 determinants-of-health#tab=tab 1. 32 480 Bennett JM, Reeves G, Billman GE, Sturmberg JP. Inflammation-nature's way to efficiently respond to all 25. 33 481 types of challenges: implications for understanding and managing "the epidemic" of chronic diseases. Frontiers in 34 482 medicine. 2018:316. 35 483 Chapman CR, Tuckett RP, Song CW. Pain and Stress in a Systems Perspective: Reciprocal Neural, Endocrine, 26. 36 484 and Immune Interactions. YJPAI Journal of Pain. 2008;9(2):122-45. 37 485 27. Slavich GM, Tartter MA, Brennan PA, Hammen C. Endogenous opioid system influences depressive 38 486 reactions to socially painful targeted rejection life events. Psychoneuroendocrinology. 2014;49:141-9. 39 487 Marchand F, Perretti M, McMahon SB. Role of the immune system in chronic pain. Nature Reviews 28. 40 488 Neuroscience. 2005;6(7):521-32. 41 489 Jiang T, Farkas DK, Ahern TP, Lash TL, Sørensen HT, Gradus JL. Posttraumatic stress disorder and incident 29. 42 490 infections: a nationwide cohort study. Epidemiology (Cambridge, Mass). 2019;30(6):911. 43 491 Costa FF, Rosário WR, Farias ACR, de Souza RG, Gondim RSD, Barroso WA. Metabolic syndrome and COVID-30. 44 492 19: An update on the associated comorbidities and proposed therapies. Diabetes & Metabolic Syndrome: Clinical 45 493 Research & Reviews. 2020;14(5):809-14. 46 494 31. Andersson NW, Goodwin RD, Okkels N, Gustafsson LN, Taha F, Cole SW, et al. Depression and the risk of 47 495 severe infections: prospective analyses on a nationwide representative sample. International journal of 48 496 epidemiology. 2016;45(1):131-9. 49 497 Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity 32. 50 498 and treatment. Rheumatology. 2013;52(1):53-61. 51 499 Page GG. The immune-suppressive effects of pain. Madame Curie Bioscience Database [Internet]: Landes 33. 52 500 Bioscience; 2013. 53 501 34. Gowing L, Farrell M, Bornemann R, Ali R. Substitution treatment of injecting opioid users for prevention of 54 502 HIV infection. The Cochrane database of systematic reviews. 2004(4):Cd004145. 55 56 57 58 16 59

Page 17 of 26

## BMJ Open

503	35. Linda G, Michael FF, Reinhard B, Lynn ES, Robert A. Oral substitution treatment of injecting opioid users for
504	prevention of HIV infection. Cochrane Database of Systematic Reviews. 2011(8):CD004145.
505	36. Jackson KA, Bohm MK, Brooks JT, Asher A, Nadle J, Bamberg WM, et al. Invasive methicillin-resistant
506	Staphylococcus aureus infections among persons who inject drugs—six sites, 2005–2016. Morbidity and Mortality
507	Weekly Report. 2018;67(22):625.
508	37. Ronan MV, Herzig SJ. Hospitalizations related to opioid abuse/dependence and associated serious
509	infections increased sharply, 2002–12. Health Affairs. 2016;35(5):832-7.
510	38. Roy S, Ninkovic J, Banerjee S, Charboneau RG, Das S, Dutta R, et al. Opioid drug abuse and modulation of
511	immune function: Consequences in the susceptibility to opportunistic infections. Journal of Neuroimmune
512	Pharmacology. 2011;6(4):442-65.
513	39. Roy S, Wang J, Kelschenbach J, Koodie L, Martin J. Modulation of immune function by morphine:
514	implications for susceptibility to infection. Journal of Neuroimmune Pharmacology. 2006;1(1):77-89.
515	40. Tahamtan A, Tavakoli-Yaraki M, Mokhtari-Azad T, Teymoori-Rad M, Bont L, Shokri F, et al. Opioids and Viral
516	Infections: A Double-Edged Sword. Front Microbiol Frontiers in Microbiology. 2016;7.
517	41. Gomes T, Kitchen SA, Tailor L, Men S, Murray R, Bayoumi AM, et al. Trends in Hospitalizations for Serious
518	Infections Among People With Opioid Use Disorder in Ontario, Canada. J Addict Med. 2022;16(4):433-9.
519	42. Kwong JC, Ratnasingham S, Campitelli MA, Daneman N, Deeks SL, Manuel DG, et al. The impact of infection
520	on population health: results of the Ontario burden of infectious diseases study. 2012.
521	43. Naylor NR, Atun R, Zhu N, Kulasabanathan K, Silva S, Chatterjee A, et al. Estimating the burden of
522	antimicrobial resistance: a systematic literature review. Antimicrobial Resistance & Infection Control. 2018;7:1-17.
523	44. Employees CUoP. Health Care Associated Infections: A Backgrounder: Canadian Union of Public Employees;
524	2009.
525	45. Kudrina I, Puzhko S, Filion KB, Gore G, Paraskevopoulos E, Windle S, et al. Effectiveness of interventions for
526	prevention of common infections in people who use opioids: a protocol for a systematic review of systematic
527	reviews. Systematic reviews. 2021;10(1):1-8.
528	46. Puzhko S, Eisenberg MJ, Filion KB, Windle SB, Hébert-Losier A, Gore G, et al. Effectiveness of Interventions
529	for Prevention of Common Infections Among Opioid Users: A Systematic Review of Systematic Reviews. Frontiers in
530	public health. 2022;10.
531	47. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic PainUnited States,
532	2016. Jama. 2016;315(15):1624-45.
533	48. Busse JW, Craigie S, Juurlink DN, Buckley DN, Wang L, Couban RJ, et al. Guideline for opioid therapy and
534	chronic noncancer pain. CMAJ : Canadian Medical Association journal = journal de l'Association medicale
535	canadienne. 2017;189(18):E659-E66.
536	49. Kumar P, Jethwa R, Roycroft G. Chronic pain: supporting safer prescribing of analgesics. British Medical
537	Association. 2017.
538	50. NHS SCCG. Opioid Prescribing for Chronic Pain: Resource Pack. 2022 2022 [Source: nenc-
539	sunderland.icb.nhs.uk ]. Available from: https://nenc-sunderland.icb.nhs.uk/wp-content/uploads/2023/02/Opioid-
540	resource-pack.pdf?x99445.
541	51. Loret A. Usage problématique des traitements opiacés dans l'indication douleur chronique non cancéreuse
542	d'origine ostéo-articulaire : Etude descriptive prospective en soins courants [Doctorat]: UNIVERSITÉ DE TOURS; 2022.
543	52. Preux C, Bertin M, Tarot A, Authier N, Pinol N, Brugnon D, et al. Prevalence of opioid use disorder among
544	patients with cancer-related pain: a systematic review. Journal of Clinical Medicine. 2022;11(6):1594.
545	53. Volkow ND, Blanco C. The changing opioid crisis: development, challenges and opportunities. Molecular
545 546	psychiatry. 2021;26(1):218-33.
540 547	54. Cicero TJ, Ellis MS. The prescription opioid epidemic: a review of qualitative studies on the progression from
547 548	initial use to abuse. Dialogues in clinical neuroscience. 2022.
	-
549 550	55. Evans CJ, Cahill CM. Neurobiology of opioid dependence in creating addiction vulnerability. F1000Research.
550	2016;5.
551	56. Pagé MG, Kudrina I, Zomahoun HTV, Croteau J, Ziegler D, Ngangue P, et al. A systematic review of the
552	relative frequency and risk factors for prolonged opioid prescription following surgery and trauma among adults.
553	Annals of Surgery. 2020;271(5):845-54.
554	57. Ballantyne JC, Sullivan MD. Discovery of endogenous opioid systems: What it has meant for the clinician's
555	understanding of pain and its treatment. Pain Pain. 2017;158(12):2290-300.
	17
	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2023-083791 on 15 October 2024. Downloaded from http://bmjopen.bmj.com/ on June 8, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

## **BMJ** Open

1

60

2 3 556 58. Kosciuczuk U, Knapp P, Lotowska-Cwiklewska AM. Opioid-induced immunosuppression and carcinogenesis 4 557 promotion theories create the newest trend in acute and chronic pain pharmacotherapy. Clinics. 2020;75. 5 558 59. Makman MH, Dvorkin B, Stefano GB. Murine macrophage cell lines contain µ3-opiate receptors. European 6 559 journal of pharmacology. 1995;273(3):R5-R6. 7 560 60. Zhang L, Belkowski JS, Briscoe T, Rogers TJ. Regulation of mu opioid receptor expression in developing T 8 561 cells. Journal of Neuroimmune Pharmacology. 2012;7:835-42. 9 Raffaeli W, Malafoglia V, Bonci A, Tenti M, Ilari S, Gremigni P, et al. Identification of MOR-positive B cell as 562 61. 10 563 possible innovative biomarker (Mu Lympho-Marker) for chronic pain diagnosis in patients with fibromyalgia and 11 564 osteoarthritis diseases. Int. 2020;21(4):1499. 12 565 Maher DP, Walia D, Heller NM. Morphine decreases the function of primary human natural killer cells by 62. 13 566 both TLR4 and opioid receptor signaling. Brain, behavior, and immunity. 2020;83:298-302. 14 Machelska H, Celik MÖ. Opioid receptors in immune and glial cells—implications for pain control. Frontiers 567 63. 15 568 in immunology. 2020;11:300. 16 569 Roeckel L-A, Le Coz G-M, Gavériaux-Ruff C, Simonin F. Opioid-induced hyperalgesia: cellular and molecular 64. 17 mechanisms. Neuroscience. 2016;338:160-82. 570 18 571 65. Franchi S, Moschetti G, Amodeo G, Sacerdote P. Do all opioid drugs share the same immunomodulatory 19 572 properties? A review from animal and human studies. Frontiers in Immunology. 2019;10:2914. 20 573 Inagi T, Suzuki M, Osumi M, Bito H. Remifentanil-based anaesthesia increases the incidence of 66. 21 574 postoperative surgical site infection. Journal of Hospital Infection. 2015;89(1):61-8. 22 575 67. Davis MP. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of 23 576 pain. The journal of supportive oncology. 2012. 24 577 Manhapra A. Complex Persistent Opioid Dependence—an Opioid-induced Chronic Pain Syndrome. Current 68. 25 578 treatment options in oncology. 2022:1-15. 26 579 69. Daniell HW. Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control 27 580 of nonmalignant pain. The Journal of Pain. 2008;9(1):28-36. 28 Daniell HW. DHEAS deficiency during consumption of sustained-action prescribed opioids: evidence for 581 70. 29 582 opioid-induced inhibition of adrenal androgen production. The Journal of Pain. 2006;7(12):901-7. 30 583 71. Wiese AD, Griffin MR, Schaffner W, Stein CM, Greevy RA, Mitchel Jr EF, et al. Long-acting opioid use and the 31 584 risk of serious infections: a retrospective cohort study. Clinical Infectious Diseases. 2019;68(11):1862-9. 32 585 Sing DC, Barry JJ, Cheah JW, Vail TP, Hansen EN. Long-acting opioid use independently predicts 72. 33 586 perioperative complication in total joint arthroplasty. The Journal of arthroplasty. 2016;31(9):170-4. e1. 34 587 73. Sacerdote P. Opioid-induced immunosuppression. Current opinion in supportive and palliative care. 35 2008;2(1):14-8. 588 36 589 74. Jacobs R, Karst M, Scheinichen D, Bevilacqua C, Schneider U, Heine J, et al. Effects of fentanyl on cellular 37 590 immune functions in man. Int J Immunopharmacol. 1999;21(7):445-54. 38 591 75. Liu Z, Gao F, Tian Y. Effects of morphine, fentanyl and tramadol on human immune response. Journal of 39 592 Huazhong University of Science and Technology. 2006;26:478-81. 40 593 Rodriguez-Vita J, Lawrence T. The resolution of inflammation and cancer. Cytokine & growth factor reviews. 76. 41 594 2010;21(1):61-5. 42 43 595 77. Roy S, Wang J, Kelschenbach J, Koodie L, Martin J. Modulation of immune function by morphine: 596 implications for susceptibility to infection. Journal of Neuroimmune Pharmacology. 2006;1:77-89. 44 597 45 78. Sacerdote P, Manfredi B, Mantegazza P, Panerai AE. Antinociceptive and immunosuppressive effects of 598 46 opiate drugs: a structure-related activity study. British journal of pharmacology. 1997;121(4):834-40. 47 599 79. Marks LR, Munigala S, Warren DK, Liang SY, Schwarz ES, Durkin MJ. Addiction medicine consultations reduce 600 readmission rates for patients with serious infections from opioid use disorder. Clinical Infectious Diseases. 48 2019;68(11):1935-7. 49 601 50 602 Allen B, Basaraba C, Corbeil T, Rivera BD, Levin FR, Martinez DM, et al. Racial differences in COVID-19 80. 51 603 severity associated with history of substance use disorders and overdose: Findings from multi-site electronic health 52 604 records in New York City. Preventive Medicine. 2023;172:107533. 53 605 Eidenschink B, Stenzel A, Michael Y, Alwahab U, Kurniali P, Guerrero D. Opioid use prior to admission for 81. 54 606 chemotherapy induced febrile neutropenia is associated with increased documented infection, sepsis, and death. 55 607 Journal of Infection and Chemotherapy. 2021;27(4):568-72. 56 57 58 18 59

609

82.

1 2 3

4

60

#### **BMJ** Open


	pen
Tuan W-J, Spotts H, Zgierska AE, Lennon RP. COVID-19 outcomes among adult patients treated with long- pioid therapy for chronic non-cancer pain in the USA: a retrospective cohort study. BMJ open. (11):e056436.	
Oh T-K, Song I-A, Lee J, Eom W, Jeon Y-T. Musculoskeletal disorders, pain medication, and in-hospital among patients with COVID-19 in South Korea: a population-based cohort study. International journal of nental research and public health. 2021;18(13):6804.	f <b>blished</b>
Alrawashdeh M, Klompas M, Kimmel S, Larochelle MR, Gokhale RH, Dantes RB, et al. Epidemiology, es, and Trends of Patients With Sepsis and Opioid-Related Hospitalizations in U.S. Hospitals. Critical care	, as
e. 2021;49(12):2102-11. Pirkle S, Reddy S, Bhattacharjee S, Shi LL, Lee MJ. Chronic Opioid Use Is Associated With Surgical Site After Lumber Surjey, Salas, 2020;47(12):827-42	136/br ected
After Lumbar Fusion. Spine. 2020;45(12):837-42. Edelman EJ, Gordon KS, Crothers K, Akgün K, Bryant KJ, Becker WC, et al. Association of Prescribed Opioids creased Risk of Community-Acquired Pneumonia Among Patients With and Without HIV. JAMA internal	10.1136/bmjopen-2023-083791 Protected by copyright, incluc
e. 2019. Oh TK, Song I-A, Lee JH, Lim C, Jeon Y-T, Bae H-J, et al. Preadmission chronic opioid usage and its association -day mortality in critically ill patients: a retrospective cohort study. British journal of anaesthesia.	023-083 right, inc
2(6):e189-e97. Khosrow-Khavar F, Kurteva S, Cui Y, Filion KB, Douros A. Opioids and the Risk of Infection: A Critical Appraisa harmacologic and Clinical Evidence. Expert opinion on drug metabolism & toxicology. 2019;15(7):565-75.	791 on . cluding
Bell KL, Shohat N, Goswami K, Tan TL, Kalbian I, Parvizi J. Preoperative opioids increase the risk of the trick of the the tisk of the trick of the total joint arthroplasty. The Journal of arthroplasty. 2018;33(10):3246-51. e1.	for use
Zhang R, Meng J, Lian Q, Chen X, Bauman B, Chu H, et al. Prescription opioids are associated with higher in patients diagnosed with sepsis: a retrospective cohort study using electronic health records. PloS one. (1):e0190362.	bber 20; s relations
Wiese AD, Griffin MR, Schaffner W, Stein CM, Greevy RA, Mitchel EF, Jr., et al. Opioid Analgesic Use and Invasive Pneumococcal Diseases: A Nested Case-Control Study. Annals of internal medicine. B(6):396-404.	
Colombel J-F, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'Haens G, et al. The safety of vedolizumab for e colitis and Crohn's disease. Gut. 2017;66(5):839-51.	perieu and d
Rozell JC, Courtney PM, Dattilo JR, Wu CH, Lee G-C. Preoperative opiate use independently predicts narcotic otion and complications after total joint arthroplasty. The Journal of arthroplasty. 2017;32(9):2658-62. Wiese AD, Griffin MR, Stein CM, Mitchel EF, Grijalva CG. Opioid Analgesics and the Risk of Serious Infections	from (ABI
Patients With Rheumatoid Arthritis: A Self-Controlled Case Series Study. ARTHRITIS & RHEUMATOLOGY. (2):323-31.	<b>-</b>
Li Y, Stocchi L, Cherla D, Liu X, Remzi FH. Association of preoperative narcotic use with postoperative ations and prolonged length of hospital stay in patients with Crohn disease. JAMA surgery. 2016;151(8):726-	—· ()
Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, et al. Serious infection and y in patients with crohn's disease: More than 5 years of follow-up in the TREAT registry. American Journal of Interology. 2012;107(9):1409-22.	
Dublin S, Walker RL, Jackson ML, Nelson JC, Weiss NS, Korff M, et al. Use of Opioids or Benzodiazepines and Pneumonia in Older Adults: A Population-Based Case–Control Study. Journal of the American Geriatrics 2011;59(10):1899-907.	on June ilar tech
Schwacha MG, McGwin G, Hutchinson CB, Cross JM, MacLennan PA, Rue LW. The contribution of opiate cs to the development of infectious complications in burn patients. The American journal of surgery 2(1):82-6.	8, 2025 nologie
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational nepidemiology: a proposal for reporting. Jama. 2000;283(15):2008-12.	s.
Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic of interventions: John Wiley & Sons; 2019.	nce Bit
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for tic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic reviews. 2015;4(1):1-9.	oliograț
19	) )
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	del

BMJ O

term opioid therapy for chronic non-cancer pain in the USA: a r 5 610 2021;11(11):e056436. 6 611 83. Oh T-K, Song I-A, Lee J, Eom W, Jeon Y-T. Musculoskeletal dis 7 612 mortality among patients with COVID-19 in South Korea: a population-base 8 613 environmental research and public health. 2021;18(13):6804. 9 614 Alrawashdeh M, Klompas M, Kimmel S, Larochelle MR, Gokha 84. 10 615 Outcomes, and Trends of Patients With Sepsis and Opioid-Related Hosp 11 616 medicine. 2021;49(12):2102-11. 12 617 85. Pirkle S, Reddy S, Bhattacharjee S, Shi LL, Lee MJ. Chronic Opi 13 618 Infection After Lumbar Fusion. Spine. 2020;45(12):837-42. 14 619 86. Edelman EJ, Gordon KS, Crothers K, Akgün K, Bryant KJ, Becker W 15 620 With Increased Risk of Community-Acquired Pneumonia Among Patient 16 621 medicine. 2019. 17 622 87. Oh TK, Song I-A, Lee JH, Lim C, Jeon Y-T, Bae H-J, et al. Preadmissio 18 623 with 90-day mortality in critically ill patients: a retrospective cohort 19 624 2019;122(6):e189-e97. 20 625 Khosrow-Khavar F, Kurteva S, Cui Y, Filion KB, Douros A. Opioids an 88. 21 626 of the Pharmacologic and Clinical Evidence. Expert opinion on drug metab 22 627 89. Bell KL, Shohat N, Goswami K, Tan TL, Kalbian I, Parvizi J. P 23 628 periprosthetic joint infection after total joint arthroplasty. The Journal of a 24 629 90. Zhang R, Meng J, Lian Q, Chen X, Bauman B, Chu H, et al. Prescr 25 630 mortality in patients diagnosed with sepsis: a retrospective cohort study 26 631 2018;13(1):e0190362. 27 Wiese AD, Griffin MR, Schaffner W, Stein CM, Greevy RA, Mitch 632 91. 28 Risk for Invasive Pneumococcal Diseases: A Nested Case-Control 633 29 634 2018;168(6):396-404. 30 635 92. Colombel J-F, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'Ha 31 636 ulcerative colitis and Crohn's disease. Gut. 2017;66(5):839-51. 32 637 93. Rozell JC, Courtney PM, Dattilo JR, Wu CH, Lee G-C. Preoperative o 33 638 consumption and complications after total joint arthroplasty. The Journal 34 639 94. Wiese AD, Griffin MR, Stein CM, Mitchel EF, Grijalva CG. Opioid Ar 35 640 Among Patients With Rheumatoid Arthritis: A Self-Controlled Case Serie 36 641 2016;68(2):323-31. 37 642 Li Y, Stocchi L, Cherla D, Liu X, Remzi FH. Association of preop 95. 38 643 complications and prolonged length of hospital stay in patients with Crohn 39 644 34. 40 645 96. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond 41 646 42 mortality in patients with crohn's disease: More than 5 years of follow-up 647 Gastroenterology. 2012;107(9):1409-22. 43 648 Dublin S, Walker RL, Jackson ML, Nelson JC, Weiss NS, Korff M, et 44 97. 649 Risk of Pneumonia in Older Adults: A Population-Based Case-Control S 45 46 650 Society. 2011;59(10):1899-907. 47 651 98. Schwacha MG, McGwin G, Hutchinson CB, Cross JM, MacLennar 48 652 analgesics to the development of infectious complications in burn pat 49 653 2006;192(1):82-6. 50 654 99. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie 51 655 studies in epidemiology: a proposal for reporting. Jama. 2000;283(15):200 52 656 Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, 100. 53 657 reviews of interventions: John Wiley & Sons; 2019. 54 658 101. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrev 55 659 systematic review and meta-analysis protocols (PRISMA-P) 2015 statemer 56 57 58 59

102. Treede R-D, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, et al. A classification of chronic pain for ICD-11. Pain. 2015;156(6):1003. 103. Morgan RL, Whaley P, Thayer KA, Schünemann HJ. Identifying the PECO: a framework for formulating good questions to explore the association of environmental and other exposures with health outcomes. Environment international. 2018;121(Pt 1):1027. Babineau J. Product review: Covidence (systematic review software). Journal of the Canadian Health 104. Libraries Association/Journal de l'Association des bibliothèques de la santé du Canada. 2014;35(2):68-71. Cohen J. The effect size. Statistical power analysis for the behavioral sciences. 1988:77-83. 105. 106. McHugh ML. Interrater reliability: the kappa statistic. Biochemia medica. 2012;22(3):276-82. 107. Practice CE, Care Oo. EPOC resources for review authors. Cochrane Effective Practice and Organization Care Oxford (UK); 2017. 108. Project EPHP. Quality Assessment Tool for Quantitative Studies. 2023 [Available from: https://www.ephpp.ca/quality-assessment-tool-for-quantitative-studies/. Thomas B, Ciliska D, Dobbins M, Micucci S. A process for systematically reviewing the literature: providing 109. the research evidence for public health nursing interventions. Worldviews on Evidence-Based Nursing. 2004;1(3):176-84. 110. Armijo-Olivo S, Stiles CR, Hagen NA, Biondo PD, Cummings GG. Assessment of study quality for systematic reviews: a comparison of the Cochrane Collaboration Risk of Bias Tool and the Effective Public Health Practice Project Quality Assessment Tool: methodological research. Journal of evaluation in clinical practice. 2012;18(1):12-8. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for 111. reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Journal of clinical epidemiology. 2009;62(10):e1-e34. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and 112. elaboration: updated guidance and exemplars for reporting systematic reviews. bmj. 2021;372. Cochrane. ReviewManager (RevMan) is Cochrane's bespoke software for writing Cochrane Reviews. 2020 113. [Available from: https://training.cochrane.org/online-learning/core-software/revman. 114. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in medicine. 2002;21(11):1539-58. Thota RS, Ramkiran S, Garg R, Goswami J, Baxi V, Thomas M. Opioid free onco-anesthesia: Is it time to 115. convict opioids? A systematic review of literature. Journal of anaesthesiology, clinical pharmacology. 2019;35(4):441. Toleska M, Dimitrovski A. Is opioid-free general anesthesia more superior for postoperative pain versus 116. opioid general anesthesia in laparoscopic cholecystectomy? prilozi. 2019;40(2):81-7. Salas J, Scherrer JF, Schneider FD, Sullivan MD, Bucholz KK, Burroughs T, et al. New-onset depression 117. following stable, slow, and rapid rate of prescription opioid dose escalation. Pain. 2017;158(2):306-12. 118. Scherrer J. New-onset depression linked to prolonged opioid use, not dose. Reactions. 2016;1586:11-30. 119. Jensen MK, Thomsen AB, Hojsted J. 10-year follow-up of chronic non-malignant pain patients: Opioid use, health related quality of life and health care utilization. European Journal of Pain. 2006;10(5):423-33. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation 120. of the Opioid Risk Tool. Pain medicine. 2005;6(6):432-42. 121. Guyatt GH, Oxman AD, Schünemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. Journal of clinical epidemiology. 2011;64(4):380-2. 

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml



Protected by copyright, including for uses related

# Reporting checklist for protocol of a systematic review and meta analysis.

Based on the PRISMA-P guidelines.

# Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-Preporting guidelines, and cite them as:

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.

Syst Rev. 2015;4	1/1).1		
5yst nev. 2013,4	+(1).1.		
			_
			P
		Reporting Item	Nun
Title			
Identification	<u>#1a</u>	Identify the report as a protocol of a systematic review	1
Update	#1b	If the protocol is for an update of a previous systematic	N/A
		review, identify as such	
	For po	er review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

BMJ Open: first published as 10.1136/bmjopen-2023-083791 on 15 October 2024. Downloaded from http://bmjopen.bmj.com/ on June 8, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) .

1 2 3	Registration			
4 5		<u>#2</u>	If registered, provide the name of the registry (such as	5
6 7 8			PROSPERO) and registration number	
9 10 11 12 13 14 15 16	Authors			
	Contact	<u>#3a</u>	Provide name, institutional affiliation, e-mail address of all	1
			protocol authors; provide physical mailing address of	
17 18 19			corresponding author	
20 21 22	Contribution	<u>#3b</u>	Describe contributions of protocol authors and identify the	13
23			guarantor of the review	
24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41	Amendments			
		<u>#4</u>	If the protocol represents an amendment of a previously	6
			completed or published protocol, identify as such and list	
			changes; otherwise, state plan for documenting important	
			protocol amendments	
	Support			
42 43	Sources	<u>#5a</u>	Indicate sources of financial or other support for the review	13
44 45 46 47 48 49 50 51 52 53 54 55	Sponsor	<u>#5b</u>	Provide name for the review funder and / or sponsor	N/A
	Role of sponsor or	<u>#5c</u>	Describe roles of funder(s), sponsor(s), and / or institution(s),	N/A
	funder		if any, in developing the protocol	
	Introduction			
56 57 58	Rationale	<u>#6</u>	Describe the rationale for the review in the context of what is	2
59 60		For pee	er review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

BMJ Open: first published as 10.1136/bmjopen-2023-083791 on 15 October 2024. Downloaded from http://bmjopen.bmj.com/ on June 8, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

1 2			already known	
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Objectives	<u>#7</u>	Provide an explicit statement of the question(s) the review will	5
			address with reference to participants, interventions,	
			comparators, and outcomes (PICO)	
	Methods			
	Eligibility criteria	<u>#8</u>	Specify the study characteristics (such as PICO, study design,	7
			setting, time frame) and report characteristics (such as years	
			considered, language, publication status) to be used as	
21			criteria for eligibility for the review	
22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38	Information	#9	Describe all intended information sources (such as electronic	7
	sources	<u>#0</u>	databases, contact with study authors, trial registers or other	,
	3001063		grey literature sources) with planned dates of coverage	
			grey interature sources, with planned dates of coverage	
	Search strategy	<u>#10</u>	Present draft of search strategy to be used for at least one	7
			electronic database, including planned limits, such that it	
			could be repeated	
39 40	Study records -	<u>#11a</u>	Describe the mechanism(s) that will be used to manage	8
41 42 43	data management		records and data throughout the review	
44 45 46	Study records -	<u>#11b</u>	State the process that will be used for selecting studies (such	8
40 47 48	selection process		as two independent reviewers) through each phase of the	
49 50 51 52 53			review (that is, screening, eligibility and inclusion in meta-	
			analysis)	
54 55	Study records -	<u>#11c</u>	Describe planned method of extracting data from reports	9
56 57 58	data collection		(such as piloting forms, done independently, in duplicate), any	
58 59 60		For pee	r review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Page 25 of 26

BMJ Open

_				
1 2 3 4 5 6 7 8 9 10	process		processes for obtaining and confirming data from investigators	
	Data items	<u>#12</u>	List and define all variables for which data will be sought	9
			(such as PICO items, funding sources), any pre-planned data	
			assumptions and simplifications	
11 12	Outcomes and	<u>#13</u>	List and define all outcomes for which data will be sought,	9
13 14	prioritization		including prioritization of main and additional outcomes, with	
15 16 17			rationale	
18 19 20	Risk of bias in	<u>#14</u>	Describe anticipated methods for assessing risk of bias of	10
21 22	individual studies		individual studies, including whether this will be done at the	
23 24			outcome or study level, or both; state how this information will	
25 26			be used in data synthesis	
27 28 29	Data synthesis	<u>#15a</u>	Describe criteria under which study data will be quantitatively	10
30 31 32			synthesised	
33 34 35	Data synthesis	<u>#15b</u>	If data are appropriate for quantitative synthesis, describe	
36 37			planned summary measures, methods of handling data and	
38 39			methods of combining data from studies, including any	
40 41 42			planned exploration of consistency (such as I2, Kendall's $\tau$ )	
43 44 45 46 47 48 49 50 51 52 53	Data synthesis	<u>#15c</u>	Describe any proposed additional analyses (such as	11
			sensitivity or subgroup analyses, meta-regression)	
	Data synthesis	<u>#15d</u>	If quantitative synthesis is not appropriate, describe the type	12
			of summary planned	
54 55 56	Meta-bias(es)	<u>#16</u>	Specify any planned assessment of meta-bias(es) (such as	12
57 58			publication bias across studies, selective reporting within	
59 60		For pee	r review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2			studies)	BMJ Op
2 3 4	Confidence in	<u>#17</u>	Describe how the strength of the body of evidence will be	en: firs
5 6	cumulative		assessed (such as GRADE)	t publi
7 8 9	evidence			shed a
10 11 12 13 14	None The PRISMA Commons Attributio	-P elab on Licer	oration and explanation paper is distributed under the terms of terms of the terms of the terms of te	BMJ Open: first published as 10.1136/bmjopen-2023-083791 Protected by copyright, includ ive creative e
15 16	https://www.goodre	ports.o	rg/, a tool made by the EQUATOR Network in collaboration with	ppen-2 / copy
17 18 19	Penelope.ai		0.	.023-08; right, ir
20 21				3791 on ncluding
22 23				n 15 C ng for
24 25				October 2024. Enseigneme r uses related
26 27				ignerr elatec
28 29				
30 31				Downloaded int Superieur to text and di
32 33				
34 35				from http:/ (ABES) . Ita mining,
36 37				g, Al t
38 39				/bmjopen.bmj.com/ on June 8, 2025 at Agence Bibliographique de I Al training, and similar technologies.
40 41				n.bmj 1g, an
42 43				d sim
44 45				ilar te
46 47				une 8
48				, 202: blogie
49 50				s. s.
51 52				genc
53 54				ë Bib
55				oliogr
56 57				aphi
58 59				que d
60		For pe	er review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	e

### Risk of infections among persons treated with opioids for chronic pain: A systematic review and meta-analysis protocol.

Journal:	BMJ Open
Manuscript ID	bmjopen-2023-083791.R1
Article Type:	Protocol
Date Submitted by the Author:	26-Aug-2024
Complete List of Authors:	Kudrina, Irina; McGill University, Family Medicine Department; Research Institute McGill University Health Center Page, G; Université de Montréal, Anesthesiology and Pain Medicine Choinière, Manon; Centre hospitalier de l'Université de Montréal (CHUM) Research Center, ; Université de Montréal, Department of Anesthesiology Shir, Yoram; McGill University, Anesthesia Eisenberg, Mark; McGill University, Cardiology; Lady Davis Institute for Medical Research Centre for Clinical Epidemiology Ben-Sasson, Maayan; McGill University Faculty of Medicine and Health Sciences Lebouché, Bertrand; McGill University Faculty of Medicine and Health Sciences, Chronic Viral Illness Service, McGill University Health Centre; McGill University Faculty of Medicine and Health Sciences, Department of Family Medicine, McGill University Puzhko, Svetlana; University Bielefeld, Department of General Practice and Family Medicine
<b>Primary Subject Heading</b> :	Medical management
Secondary Subject Heading:	General practice / Family practice, Infectious diseases, Medical management
Keywords:	INFECTIOUS DISEASES, IMMUNOLOGY, PAIN MANAGEMENT, Meta- Analysis, Systematic Review

# SCHOLARONE<sup>™</sup> Manuscripts

1 2		
3	1	Risk of infections among persons treated with opioids for chronic pain: A systematic
4 5	2	review and meta-analysis protocol
6 7	3	Irina Kudrina, <sup>1,2,3,4</sup> M. Gabrielle Pagé, <sup>5</sup> Manon Choinière, <sup>5</sup> Yoram Shir, <sup>2</sup> Mark J. Eisenberg, <sup>6</sup>
8 9	4	Maayan BenSasoon, <sup>2</sup> Bertrand Lebouché, <sup>1,3,7</sup> Svetlana Puzhko <sup>8</sup>
10	-	
11 12	5	Author affiliations
13 14	6	<sup>1</sup> Faculty of Medicine and Health Sciences, Family Medicine Department, McGill University,
15	7	Montreal, Quebec, Canada
16 17	8	<sup>2</sup> Alan Edwards Pain Management Unit, Anesthesia Department, Faculty of Medicine and Health
18 19	9	Sciences, McGill University, Montreal, Quebec, Canada
20	10	<sup>3</sup> Division of Secondary Care, Faculty of Medicine and Health Sciences, McGill University
21 22	11	<sup>4</sup> BRAiN& neurosciences, Research Institute, McGill University Health Center, Montreal, Quebec,
23 24	12	Canada
25	13	<sup>5</sup> Department of Anesthesiology and Pain Medicine, Faculty of Medicine, Université de
26 27	14	Montréal, Montreal, Quebec, Canada
28 29	15	Research center, Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada
30	16	<sup>6</sup> Center for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General
31 32	17	Hospital, Montreal, QC, Canada
33 34	18	Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada
35	19	Departments of Epidemiology, Biostatistics and Occupational Health, McGill University,
36 37	20	Montreal, QC, Canada
38 39	21	Division of Cardiology, Jewish General Hospital, McGill University, Montreal, QC,
40	22	<sup>7</sup> Centre for Outcomes Research & Evaluation, Research Institute of the McGill University
41 42	23	Health Centre, Montreal, Quebec, Canada
43 44	24	Chronic Viral Illness Service, Division of Infectious Disease, Department of Medicine, McGill
45	25	University Health Centre, Montreal, Quebec, Canada
46 47	26	<sup>8</sup> Department of General Practice and Family Medicine, University of Bielefeld, Germany
48 49	27	
50 51	28	Corresponding author: Irina Kudrina Alan Edwads Pain Management Unit, McGill University
52	29	Anesthesia Department, 1650 ave. Cedar, Montreal General Hospital, Montreal, Quebec, Canada
53 54	30	H3G1A4 Email: Irina.kudrina@mcgill.ca
55 56	31	
57		
58 59		1
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

### 32 ABSTRACT

Introduction. Millions of persons with chronic pain across North America and Europe use opioids. While immunosuppressive properties of opioids are associated with risks of infections, these outcomes could be mitigated through careful patient selection and monitoring practices, when appropriate. It is important to recognize that some patients do benefit from a carefully tailored opioid therapy. Enough primary studies have been published to date regarding the opioids' role in potential immunosuppression presenting as an increased rate of infection acquisition, infectious complications and mortality. There is thus a critical need for a consensus in this area.

Methods and Analysis. Methodology is based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement, the MOOSE Guidelines for Meta-Analyses and Systematic Reviews of Observational Studies, and the Cochrane Handbook for Systematic Review of Interventions. We plan to systematically search Ovid MEDLINE, CINAHL, PsycINFO, EMB Review, EMBASE, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, and Google Scholar databases from the inception date to December 2023. Primary studies full text reporting measurable outcomes in adults with chronic pain, all routes of opioid use, all types of infections and all settings will be included. We will identify a scope of reported infections, and the evidence on the association of opioid use (including specific opioid, dosage, formulation, and duration of use) with the risk of negative infectious outcomes. Opioid use-associated outcomes, comparing opioid use to another opioid or a non-opioid medication will be reported. Meta-analysis will incorporate individual risk factors. If data are insufficient, results will be synthesized narratively. Publication bias and confounding evaluation will be performed. The GRADE framework will be used. 

Ethics and Dissemination. Approval for the use of published data is not required. Results will be
published, presented at conferences, and discussed in deliberative dialogue groups.

## 57 STRENGTHS AND LIMITATIONS OF THIS STUDY

• First-of-its-kind extensive comprehensive systematic review planned on the topic

• Inclusion of all types of opioids, doses, routes of administrations (except illicit self-injection)

- Multi-database and multi-lingual systematic search
- Limited to quantitative studies reporting measurable outcomes only
- Not searching for specific infectious agents might result in some pertinent studies being missed

#### **INTRODUCTION**

The COVID-19 pandemic brought to light synergistic public health crises of poorly managed chronic pain (CP) (1) and rising opioid prescribing rates (2, 3) culminating in increased prevalence of opioid use associated complications like acute overdoses or chronic hormonal and immune disturbances (4-6). CP, defined as pain lasting more than three months (7), is common worldwide, affecting 18% of the population across developing nations (8) to more than 20% of population in the United States (U.S.) and Canada (9). About 11% of young adults (10) and up to 85% of elderly patients (11) live with CP, including pain-related disability (12, 13) frequently associated with opioid use. Reportedly, the direct and indirect costs to society from pain and opioid crises pre-pandemic in Canada ranged anywhere from \$38.3 to \$40.4 billion annually (14). 

The prevalence of opioid use in Canada is estimated more than 12% of the population (15), making Canada one of the leading opioid consumers in the world (988 mg morphine equivalent per 1000 inhabitants/day), with similar trends observed across the U.S. and European countries like Germany (16) and Netherlands (17). With age, the proportion of patients with CP using licit and illicit opioids increases (18), and so does the prevalence of opioid-related fatal and non-fatal adverse effects. In 2022 alone, the Canadian government reported ~20 opioid-related deaths and hundreds of hospitalizations daily (19). These statistics, however, do not include a much higher prevalence of opioid use associated long-term sequela. 

Multimorbidity (20) and low socio-economic status (SES) are linked with CP (21) and opioid use, confounding the development of immunosuppression and poor health (22, 23) (Figure 1). CP disproportionately affects persons from marginalized (racialized, poor etc.) communities and the elderly (11, 24). As the World Health Organization pointed, "... health and illness follow a social gradient: the lower the socioeconomic position, the worse the health" (25). Furthermore, an overall link between multimorbidity, polypharmacy, neuro-immune disturbances and infections appears well established (26). Several common chronic disease states like metabolic syndrome, inflammatory arthritis, major depression, various pain syndromes, prolonged stress, and post-traumatic stress disorder (27-29) are associated with long-term disturbances of the hypothalamicpituitary-adrenal (HPA) axis, pro-inflammatory (e.g., cytokine-driven) systemic changes (27, 28), and various degrees of immunosuppression. Unsurprisingly, the risk of negative infectious 

BMJ Open: first published as 10.1136/bmjopen-2023-083791 on 15 October 2024. Downloaded from http://bmjopen.bmj.com/ on June 8, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

#### BMJ Open

Our knowledge of opioid-associated infections is not new (35-38). It is important to distinguish between infections resulting from unsterile injection practices, such as those leading to bloodborne infections like HIV, osteomyelitis, skin and epidural abscesses, and infective endocarditis (38-41), and infections resulting from the immunosuppressive effects of opioids, which impact immune-related receptors in the human body and affect innate and adaptive immune system responses. The recent reviews (42, 43) of the pre-clinical and clinical evidence postulate that the most plausible mechanism of immunosuppression by opioids would involve mu-opioid receptors expressed by mammalian tissues. In addition, opioids affect intestinal microbiome, permeability and bacterial dissemination as well as the modulation of the central nervous system-HPA axis. Together, these lead to a plethora of closely intertwined effects involving suppression of immune cells proliferation, reduction in anti-bacterial activity, migration and antigen presentation by the innate immune system (macrophages, neutrophiles, dendritic, NK and mast cell activation) and several changes in adaptive immunity (T and B cells). 

In the U.S. (2002-2012), hospitalizations related to opioids and opioid-associated infections cost American Medicaid \$15 billion and \$700 million respectively (38). In the province of Ontario (Canada), a significant increase in the rates of infective endocarditis (167%), spinal infections (394%), skin and soft tissue infections (147%) is also reported (2013-2019). The ten highest burden pathogens of interest (S. pneumoniae, Escherichia coli, Human Papillomavirus, Hepatitis B virus, HIV, HCV, Staphylococcus aureus, influenza virus, Clostridium difficile, rhinovirus) have accounted for >65% of health-adjusted life years lost due to premature morbidity and mortality (44). It is estimated that only antimicrobial-resistant (45) and hospital-acquired (46) infections cost Canadians additional \$3.5 billion a year. 

50 121

The importance of the confluent effect of the opioid-induced immunosuppression and the risk of infections is difficult to overestimate. There is an already good understanding (47, 48) of the effectiveness of the HIV and hepatitis C infections prevention strategies in persons who inject Page 5 of 30

#### **BMJ** Open

illicit opioids. In the field of pain however, the CDC (12, 49), Canadian (50), and European (51,
52) opioid prescribing guidelines although acknowledge the possibility of endocrine and immune
disturbances, yet do not offer any guidance on balancing opioid use and risk of infections in these
populations. No consensus has been reached regarding the risk of specific opioids and no
corresponding prevention strategies have been identified.

Opioid use for CP presents a spectrum ranging from a sub-group of patients taking occasional small doses of opioids to patients treated with regular medium-to-high-dose opioid therapy, and all the way to another sub-group of patients who live with concomitant CP and opioid use disorder. It is estimated that >20% of patients with musculoskeletal CP overconsume or misuse opioids, and about 15% live with opioid use disorder (53). Similarly, in a SR of 15 studies (54) looking at cancer-related CP, opioid misuse was reported being as high as 27.8%, and opioid use disorder ranged up to 20%. The data thus converge to demonstrate that although most patients with CP do not engage in risky behaviours, therapeutic and recreational uses might not always be easily separable. Many patients diagnosed with opioid misuse or use disorders, had their first exposure to an opioid in the context of CP diagnoses (55-57). More so, persistent opioid use could also develop post-acute trauma and surgery (58), leading to chronic opioid toxicity and its sequela. 

Opioids belong to a diverse class of molecules, including natural ones like opium, morphine and codeine, their derivatives (e.g., heroin, hydromorphone, oxycodone) and synthetic ones (buprenorphine, tramadol, fentanyl etc.) They exert therapeutic and non-therapeutic effects via opioid receptors of the endogenous opioid system (4, 59), one of the most omnipresent neuro-transmitter systems in the mammalian organism closely involved in analgesia, stress and immune responses (4-6, 27, 60). It was shown that the mu-opioid receptors are found on immune cells like macrophages (61), T and B lymphocytes (62, 63), natural killer (64), and even glial cells (65) that provide support and protection for the neurons. Notably, opioid-induced glial changes are thought to be implicated in the development of opioid-induced hyperalgesia (abnormally increased pain) (66), a phenomenon that can drive prolonged opioid use and dose escalation. Aside from the dose and duration, immunosuppressive effects and risk of infections likely vary by specific opioid (6, 67). 

 BMJ Open: first published as 10.1136/bmjopen-2023-083791 on 15 October 2024. Downloaded from http://bmjopen.bmj.com/ on June 8, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open: first published as 10.1136/bmjopen-2023-083791 on 15 October 2024. Downloaded from http://bmjopen.bmj.com/ on June 8, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

*Clinical immunosuppression* in acute post-operative settings (e.g., abdominal surgeries) with the use of remifentanil anesthesia is associated with higher infection rates at the surgical sites when compared with fentanyl (68). Buprenorphine appears to be one of the safer options (69, 70), and long-acting opioid formulations are associated with a greater HPA axis suppression (71, 72) and a higher risk of infectious complications (73, 74) than short-acting opioids. Thus, some authors categorize opioids into "more immunosuppressive" (e.g., morphine, fentanyl, codeine, dihydrocodeine, methadone) and "less immunosuppressive" (oxycodone, tramadol, buprenorphine, hydromorphone) (75-80), although this classification lacks systematic evidence support and is not widely accepted. 

Preliminary data in CP. Despite variations in methodological approaches (81), the trends across primary studies have been pointing to the same direction. A non-systematic biophysiological review (23) laid much support to the hypothesis that opioids in general, and especially long-term opioid therapy (> 3 months), can alter parameters of the innate and adaptive immunity in patients with CP in a clinically meaningful way. A preliminary search (August 15, 2023) of the Medline Ovid and Google Scholar databases in English revealed a sample of primary and synthesis studies on the topic (1, 23, 82-88) (73, 74, 89-100), analyzing the association with serious infections (pneumonia, bacteremia. sepsis, meningitis/encephalitis, septic arthritis/osteomyelitis, endocarditis, pyelonephritis, and cellulitis), and corresponding rates of hospitalizations, ICU admissions, and mortality. The current public health crisis is primarily related to illicit fentanyl and associated analogues, rather than prescription opioids. Moreover, as the prevalence of licit (prescribed and over-the-counter pharmaceutical) and illicit (not prescribed, pharmaceutical and non-pharmaceutical) opioid use remains a serious concern, and given that sufficient literature has been published to date on the topic, there is a critical need for systematically synthesized knowledge on the risk of opioid-use associated infections in persons with CP, outside of the illicit self-injecting practices. To our knowledge, this SR will be the first one on the topic. It will contribute to informing clinical practice guidelines, opioid prescribing policies, and clinical practices across Canada and internationally. 

185 Registration. The protocol was registered in PROSPERO on 18 March 2023
186 (CRD42023402812)

187	
188	<b>REVIEW QUESTIONS AND OBJECTIVES</b>
189	Review questions
190	The overarching review question for this SR is: What is the evidence on the association of opioid
191	use with increased risks for infections, re-infections, and negative infectious outcomes among
192	persons with chronic pain using opioids (excluding illicit self-injecting practices)?
193	The secondary review question is: Does the association between the use of opioids and risks for
194	infectious outcomes depend on the specific opioid, dosage, formulation, and duration of use?
195	
196	Objectives
197	Primary objectives are to:
198	1. Identify the scope of infections in opioid users (IPO) as described in studies selected for this
199	systematic review.
200	2. Synthesize the evidence on the difference in the infection acquisition risks between persons with
201	CP who use opioids versus a comparator as available in the literature.
202	3. Synthesize the evidence on the difference in IPO-related outcomes (i.e., hospitalizations,
203	duration of hospital stays, intensive care unit (ICU) admissions, mortality, etc.) between persons
204	with CP who use opioids versus a comparator.
205	Secondary objectives (data permitting) are to:
206	1. Examine if the risk for negative IPO-related outcomes is associated with the opioid dose, opioid
207	formulation (long- vs short-acting) and duration of use.
208	2. Identify opioids associated with a higher risk of infection acquisition and/or negative IPO-
209	related outcomes.
210	3. Identify specific individual-level characteristics that may be associated with an increased risk
211	of infection acquisition and/or negative IPO-related outcomes.
212	
213	METHODS AND ANALYSIS
214	The SR methodology is based on the MOOSE Guidelines for Meta-Analyses and Systematic
215	Reviews of Observational Studies (101), and the Cochrane Handbook for Systematic Review of
	7 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
	188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 204 205 206 207 208 209 210 211 212

Interventions (102). The results will be reported according to the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) statement (103). This protocol was registered
in PROSPERO and important protocol amendments will also be documented in PROSPERO.

#### 219 **Operational definitions**

1 2 3

4 5

6

7 8 9

10

11

- 1) *Chronic pain* includes cancer pain, cancer treatment-induced pain, and non-cancer pain (7, 104).
- 221 2) *Opioids* are natural compounds, semi-synthetic or synthetic molecules exerting their main
   222 physiologic effects via opioid receptors (mu, delta, kappa). All opioids and their formulations
   223 mentioned in the identified primary studies will be included in this SR. For specific opioid
   224 names in the search strategy, please refer to Table 1.
- <sup>19</sup><sub>20</sub> 3) *IPO* include all (bacterial, viral, and fungal) infections described in studies selected for this SR.
- 21 226 4) All *routes of administration* (oral, transdermal, intravenous, intra-thecal, etc.) will be included.
- 23 227 Due to the potential risk of shared needle/syringe contamination unrelated to
   24 25 228 immunosuppressive properties of studied medicines, we will *exclude* illicit self-injections of
   26 27 229 opioids.
- 28 230 5) Various opioid use durations will be considered: acute (1-7 days), short-term (8-30 days), medium-term (>30 -120 days) and chronic (> 120 days).
- 31 32
   32
   33
   34
   35
   36) *Type of opioid use* will be categorized as *episodic* (non-daily, or one to six days a week) or continuous (daily or seven days a week).
- 234 7) *Outcomes* include infection acquisition rates, infections-related hospitalizations, duration of
   235 hospital stays, ICU admissions, and mortality.
- 236 8) *Dose reporting*. All reported doses will be recalculated in morphine equivalent daily dose
   237 (MEDD) based on the Utah university conversion table (12, 105), whenever data permit. For
   238 any studies reporting on opioids for which conversion values are not available, a narrative
   239 summary will be generated.
- 45 46 240

47

48

56 57 58

59

60

## 241 Eligibility criteria

Eligibility criteria will be defined based on the PECO approach. *Participants* are patients with CP who use opioids (with or without opioid dependence and/or opioid use disorder), and who do not self-inject illegal/recreational opioids. *Exposure* is all opioid use, except illegal self-injection of opioids and kratom plant. *Comparator* is a population from the same setting (ICU, for example)

using another opioid or a non-opioid medication. *Outcome* is the scope of the *IPO* and measurable
infection-related outcomes (see Outcome reporting) (106).

We will include all relevant primary studies reporting all routes of opioid use by adult humans, all infections (including COVID-19) during opioid use period, and all settings. We will include full texts in any language (translated with Deepl https://www.deepl.com/en/app (107) or Google Translate) reporting measurable outcomes and various designs (randomized and non-randomized trials, observational studies, case series, and mixed methods studies (quantitative portion)). Studies focusing on pediatric populations, palliative/end-of-life care, self-injection of illegal/recreational opioids, qualitative designs, opinions, commentary, abstracts, conference proceedings will be excluded. 

22 257 

# 24 258 Search strategy25

Databases. An experienced medical liaison McGill librarian will be involved. We plan to systematically search Ovid MEDLINE, CINAHL, PsycINFO, EMB Review, EMBASE, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, and Google Scholar databases from the inception date to December 2023 using a combination of medical subject headings (MeSH) and keywords. Grey literature: (Pro Quest, Dissertation and Theses; published reports) will be searched. The Keywords and MeSH terms will be entered for the concepts: "opioids", "infections", and "pain" using Boolean operator AND for: (1) all commonly used opioids (generic, brand names, and synonyms); (2) infections (all viral, bacterial, and other infections); and (3) pain (cancer, non-cancer). The search strategy will be adapted to each database (see example in Table 1.) Backward and forward citation searches will be performed 

#### 

#### Table 1. PubMed search strategy example

1 (Opioid [Mesh] OR narcotic\*[tw] OR analgetic\*[tw] OR (actiq or adolonta or amadol or analgesic\* or anpec or ardinex or asimadolin\* or astramorph or avinza or biodalgic or pethidine or buprenorphine or carfentanil or codeine or codinovo or contramal or demerol or dicodid or dihydrocodeinone or dihydrohydroxycodeinone or dihydromorphinone or dihydrone or dilaudid or dinarkon or dolantin or dolargan or dolcontral or dolosal or dolsin or duragesic or duramorph or epimorph or eucodal or exalgo or fentanest or fentanyl or fentora or fortral or heroin or hycodan or hycon or hydrocodeinonebitartrate or

1 2 3 4 5 6 7 8 9 10 11 12	
13 14 15 16 17 18 19 20 21 22 23 24 25 26	
27 28 29 30 31 32 33 34 35 36 37 38 39	
40 41 42 43 44 45 46 47 48 49 50 51 52	
52 53 54 55 56 57 58 59	

hydrocodone or hydrocodone\* or hydromorphon or hydromorphone or hydroxyacetanilide or hydroxycodeinon or hysingla or isocodeine or isonipecain or jutadol or kadian or dromoran or laudacon or levodroman or levodromoran or levo-dromoran or levorphan or levorphanol or lexir or lidol or lorcet or lortab or lydol or meperidine hydrochloride or methadone or morfin or morfine or morphia or morphin or morphine or morphinium or morphium or ms contin or n methylmorphine or narcotic or n-methylmorphine or nobligan or norco or numorphan or operidine or opiate or opioid\* or opso or oramorph sr or oripavine or oxecta or oxiconum or oxycodeinon or oxycodone or oxycone or oxycontin or oxymorphone or palladone or pancodine or pentazocine or percocet or pethidine or phentanyl or prontofort or propoxyphene or robidone or roxicet or roxicodone or skenan or sublimaze or suboxone or takadol or tapentadol or talwin or thebaine or theocodin or theradol or tiral or topalgic or tradol or tradolpuren or tradonal or tralgiol or trama or tramadol or tramadol or tramadolhameln or tramadolor or tramadorsch or tramadura or tramagetic or tramagit or tramake or tramal or tramex or tramundin or trasedal ultram or vicodin or zamudol or zohydro or zumalgic or zydol or or zytram).tw,sh,kw,kf,oa,nm

- 2 (Infections[Mesh] OR Infect\*[tw] OR communicable disease\*[tw] OR virus disease\*[tw] OR viral disease\* OR viral illness\*[tw] OR viral infection\*[tw] OR bacterial infection\*[tw])
- 3 Pain[Mesh] OR Acute Pain[tw] OR Chronic Pain[tw] OR Cancer Pain[tw] OR Pain Management[tw])

# 4 #1 AND #2 AND #3

Filters: Adults > 18 year of age

## 270

60

## 271 Study selection

272 The Covidence systematic review software (108) will be used to perform screening, quality assessment and data extraction, and to document decisions on inclusion/exclusion. First, two 273 independent reviewers will screen manuscripts by titles and abstracts. We will calculate kappa-274 statistic (inter-rater agreement) to ensure consistency of the selection process (109, 110). Before 275 screening, a stepwise calibration test will be performed on a sample of 30 studies, with the aim of 276 achieving 80% agreement between reviewers. We will report changes to the inclusion and 277 exclusion criteria that result from the calibration as deviations from the published protocol. All 278 potentially relevant studies will be carried forward at each step. The remaining full texts will be 279

#### **BMJ** Open

reviewed for eligibility independently by two researchers. Disagreements will be resolved byconsensus with a third reviewer.

#### 283 Data extraction

To extract the data, we will adopt a modified Effective Practice and Organisation of Care (EPOC) Cochrane Data Collection forms (102, 111). The extracted data will be categorized into: 1) patients' characteristics (sex at birth, gender, age, sociodemographic, psychosocial, and available medical characteristics (immunosuppression, number of co-morbidities)); 2) opioid use status (continuous, episodic or no use, opioid formulation, opioid type, and dose); 3) infection-related factors, such as infection diagnosis (e.g., pneumonia), infection type (bacterial, viral, fungal) and, if available, specific infectious agent (e.g., *Clostridium*); 4) clinical settings (e.g., community, hospital, intensive care unit); and 5) clinical disciplines (e.g., orthopedic surgery), and 6) measurable outcomes (e.g., duration of hospital stays; intensive care unit admissions) and severity (requiring intubation, mechanical ventilation, sepsis, septic shock, mortality). One researcher will extract the data and another researcher will check the extracted data for errors and plausibility. 

#### **Outcome reporting**

For *primary objective 1*, all infections reported in quantitative studies will be documented, and relevant details on the population, settings, and opioid use will be described. For primary objective 2, we will synthesize the evidence on the differences of infection acquisition risks between persons who use opioids versus a comparator. For *primary objective 3*, we will synthesize the evidence on the differences in *IPO*-related measurable outcomes (e.g., duration of hospital stays) and severity (e.g., septic shock) between persons who use opioids versus comparator. For primary objectives 2 and 3, meta-analysis of the extracted effect measures will be performed; pooled effect measures will be reported (if feasible). 

For *secondary objective* 1, if data allow, we will synthesize the evidence on the relationships between the opioid dose, duration of use, opioid formulation (long- vs short-acting) and reported *IPO* outcomes. "Opioid-naïve" period prior to exposure, when reported by the primary studies, will be recorded. For *secondary objective* 2, if data allow, we will identify specific opioids that are associated with a higher risk of infection acquisition and poor outcomes. If data allow, for *secondary objective* 3, we will identify individual risk factors (e.g., age, gender, ethnicity, comorbidities) that are associated with a higher risk of infection acquisition and poor outcomes.
Tabulated data and qualitative descriptions will be provided for *secondary objectives 1, 2 and 3*.
Studies on chronic malignant pain as well as non-malignant pain will be reported separately as

314 well as pooled.

**Risk of bias in individual studies** 

We will review included articles and assess the risk of bias for each outcome of interest. Disagreements will be discussed until a consensus is reached. In case of unresolved disagreement, a third reviewer will be invited to appraise the study. We will employ a validated EPHPP (Canadian Effective Public Healthcare Panacea Project) Ouality Assessment Tool (112) based on eight categories universally applicable to quantitative studies that has a good inter- and intra-rater reliability (113, 114). The EPHPP tool is widely cited and was chosen for its excellent properties in evaluating studies in the pain field (114). We will record the study's funding sources and authors' conflicts of interest statements. 

#### 326 Data synthesis

The PRISMA flowchart (115, 116) will be used to describe the study selection process. We will tabulate the data on included studies and their populations, the identified risk factors, and the outcome characteristics, using frequency counts. All measurable outcomes extracted from the included studies will be used in data synthesis. If two or more studies for a specific measurable outcome are available, we will perform meta-analysis using the Review Manager (RevMan) software (117). Standardized mean difference with 95% CI for continuous outcomes, and odds ratios, relative risk ratios or hazard ratios with 95% CI for dichotomous outcomes will be used in meta-analysis. Whenever possible, we will transform other effect estimates into these effect measures. Higgins' I<sup>2</sup> statistics (102, 118) (i.e., the percentage of variability in the effect size estimates due to heterogeneity) will be calculated. The I2 statistic is a relative measure of heterogeneity and will be assessed in conjunction with prediction intervals. According to Cochrane recommendations, an I<sup>2</sup> statistic of 30-60% and 50-90% may respectively represent moderate and substantial heterogeneity. Heterogeneity above 75% would be defined as considerable (119). Prediction intervals, which are easier to interpret and relate to clinical implications, estimate a prespecified (95% CI) range of treatment effects expected in future settings (120, 121). If the range 

Page 13 of 30

#### **BMJ** Open

of treatment effects shown by prediction intervals includes both positive and negative clinically relevant effects, the meta-analysis results will be considered inconclusive. Based on our pilot search, we anticipate some data heterogeneity, which will require the use of a random-effect model to calculate the pooled effect sizes. If sufficient data on the adjusted effect measures are available, we will calculate both pooled adjusted and crude effect sizes (see sensitivity analysis). If the information on the specific opioids-related (opioid dose, opioid formulation, treatment duration) and individual-level characteristics are available, we will conduct subgroup analysis and will report group-specific effect estimates. The results of meta-analysis will be presented as forest plots. If data are insufficient to conduct meta-analysis for one of the objectives, we will use a narrative approach to data synthesis. 

<sup>2</sup> 353 Sex and gender-based analysis

Integrating sex and gender is of crucial importance to our study as both variables exhibit multi-directional effects and can be confounders or effect modifiers (see Figure 1). We will apply a broad theoretical and empirical framework to understand the development of *IPOs* and underlying mechanisms, integrating up-to-date sex and gender, pain, and addiction literature. Thus, rather than focusing on the artificially binary categories such as male/female (for sex) or man/woman (for gender), we will take the real-life complexity of these characteristics into consideration. Variables from the studies that mention "sex", "biological sex", "sex assigned at birth", "male and female" and similar binary terminology, will be treated in the category of sex. The rest of the studies that mention gender-related terminology such as "man and woman", "transgender", "gender fluid", "gender nonbinary", two-spirit (Indigenous) etc. will be assigned to the gender variable. The authors of primary studies will be contacted to obtain clarifications, missing data on non-binary sex and gender categories, and their responses will be thoroughly documented. We will stratify our analysis by sex /gender categories and will report sex or gender-specific effect measures separately. We will ensure inclusion of sex and gender-specific effect measure estimates in the discussion, as well as the issue of missing non-binary data. 

io 369

370 Publication bias, confounding, sensitivity analysis and quality of cumulative evidence

*Publication bias* will be assessed examining funnel plots for each outcome, for which more than
10 studies will be included in the meta-analysis (102).

1

51

52 53

54 55

56 57 58

59

60

2		
3 4	373	
5	374	Confounding. Sex/gender, history of opioid use, the use of other immunosuppressive medications
6 7	375	etc. may have confounding or effect modifying effects in the association between opioid use and
8 9	376	risk for infectious outcomes (see Figure 1). As our pilot search showed, most studies use an
10 11	377	observational design, and thus may be prone to the confounding by indication bias. For example,
12	378	it may seem that patients prescribed opioids are likely to have a more severe disease than persons
13 14	379	not prescribed opioids, and the more severe disease may be an independent risk for infections.
15 16	380	Indeed, this scenario is possible, but not unique. Disease severity is not always reflective of the
17	381	analgesia requirements. For example, when compared to controls, patients who sustained small
18 19	382	burns and those with the largest burn surfaces, were respectively 1.73 (95% CI, 1.20 -2.49) and
20 21	383	1.02 (95% CI, 0.71–1.46) times more likely (100) receive opioids. From our clinical experience
22 23	384	and the literature, the decision to prescribe opioids is multi-fold. Thus, most public insurances in
24	385	Canada cover opioid therapy and frequently do not cover non-pharmacological treatments for CP.
25 26	386	This makes opioids an ultimate choice for the poor, not working (e.g., students, elderly) and
27 28	387	marginalised populations in Canada. Furthermore, the initial doses in opioid-naïve patients will be
29 30	388	lower than among patients taking opioids chronically. Moreover, there is an increasing emphasis
31	389	in anesthesia protocols to reduce reliance on opioid analgesics (122, 123). In addition, CP literature
32 33	390	identifies depression (124, 125), anxiety, and pain catastrophizing (126) as drivers of opioid dose
34 35	391	escalation and chronicity of use. A history of sexual abuse in men and a family and personal
36 37	392	history of other substance misuse/use disorders are known risk factors (127) for the problematic
38	393	opioid use in the future. The attempts to account for the complexity and known confounders, effect
39 40	394	modifiers, and important covariates will be made in the analysis. In case these data will be missing
41 42 43 44 45 46 47 48 49	395	from the primary studies, the authors will be contacted. If sufficient data on the important
	396	covariates are identified, a subgroup analysis will be conducted, and the subgroup-specific effect
	397	estimates will be reported. Epidemiologic biases that can lead to over-/under-estimations of effect
	398	sizes or spurious associations will be discussed as study limitations.
	399	
50	400	Sensitivity analysis. To assess the robustness of our results on each outcome of interest, we will

e will perform sensitivity analyses. First, the pooled effect size estimation will be repeated by including 401 only studies with a low risk of bias, and the results will be compared with the main analysis. 402 Second, we will compare the pooled effect estimates from randomized controlled trials and 403

Page 15 of 30

#### **BMJ** Open

observational studies. Then, we will evaluate the possible effect of covariates included in the calculation of adjusted effect sizes in original studies on the pooled effect size. For this, we will estimate the pooled crude effect size for each outcome of interest using crude (non-adjusted) effect sizes for separate studies, if available. The effect estimates will be compared with the adjusted effect estimates obtained in the main analysis. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) (128) framework will be used for the assessment of the quality of cumulative evidence for each outcome of interest. A certainty rating (very low, low, moderate, or high) will be assigned. PATIENT AND PUBLIC INVOLVEMENT Two patient representatives will be a part of the SR study team. We will report their contribution in the resulting SR manuscript. As SR results are available, we will organize downstream deliberative dialogue groups with patients, care providers and decision makers to develop the most optimal ways for knowledge uptake and implementation across clinical settings in Canada, U.S., Israel, Germany, and other European countries. ETHICS AND DISSEMINATION This review is based on already published literature thus, no ethics review is requested. Results will be published, presented at conferences, and discussed in deliberative dialogue groups. 

**Timeline for review** 

At the time of re-submission of our manuscript, we had already started database searches. 

#### **AUTHORS CONTRIBUTIONS**

Irina Kudrina: Conceptualization, writing original draft, methodology, review and editing. This author is the guarantor of the study and accepts full responsibility for the finished work and/or the conduct of the study, has access to the data, and controls the decision to publish. 

- Gaberielle Pagé: methodology, review and editing.
- Manon Choinière: methodology, review and editing.
- Yoram Shir: review and editing.

1 2		
3 4	435	Maayan BenSasoon: review and editing.
5	436	Bertrand Lebouché: review and editing.
6 7	437	Mark J. Eisenberg: review and editing.
8 9	438	Svetlana Puzhko: Conceptualization, methodology, review and editing.
10	439	
11 12	440	FUNDING STATEMENT
13 14	441	This research received no specific grant from any funding agency in the public, commercial or
15	442	from the not-for-profit sectors.
16 17	443	
18 19	444	COMPETING INTERESTS STATEMENT
20 21	445	Authors of this manuscript declare no conflict of interest and no competing interests.
22	446	MGP is supported by the Junior-2 Salary Award from the Fonds de recherche du Québec–Santé
23 24	447	(FRQS)
25 26	448	MJE holds a James McGill Professor Award from McGill University.
27	449	BL is supported by 2 career awards: a Senior Salary Award from the FRQS and the LE 250
28 29	450	(from the Quebec Ministry of Health for Researchers in Family Medicine), ; he also holds a
30 31	451	Canadian Institutes for Health Research, Strategy for Patient-Oriented Research Mentorship
32 33	452	Chair in Innovative Clinical Trials for HIV Care. He has received research support, consulting
34	453	fees and speaker fees from ViiV Healthcare, Merck, and Gilead.
35 36	454	
37 38	455	REFERENCES
39	456	
40 41	457	1. Ao G, Li A, Wang Y, Li J, Tran C, Chen M, et al. Opioid usage and COVID-19 prognosis: A systematic review
42	458	and meta-analysis. The American Journal of Emergency Medicine. 2022.
43	459	2. Canada Go. Restricting the Marketing and Advertising of Opioids 2021 [Available from:
44 45	460	https://www.canada.ca/en/health-canada/services/opioids/responding-canada-opioid-crisis/advertising-
46	461	opioid-medications.html.
47	462	3. Simha S, Ahmed Y, Brummett CM, Waljee JF, Englesbe MJ, Bicket MC. Impact of the COVID-19 pandemic on
48	463	opioid overdose and other adverse events in the USA and Canada: a systematic review. Reg Anesth Pain Med.
49 50	464	2023;48(1):37-43.
50 51	465	4. Feng Y, He X, Yang Y, Chao D, H Lazarus L, Xia Y. Current research on opioid receptor function. Current drug
52	466	targets. 2012;13(2):230-46.
53 54	467	5. Wei G, Moss J, Yuan C-S. Opioid-induced immunosuppression: is it centrally mediated or peripherally
54 55	468	mediated? Biochemical pharmacology. 2003;65(11):1761-6.
56		
57		
58		16
59		

3 4 5	469 470	6. Sun Q, Li Z, Wang Z, Wang Q, Qin F, Pan H, et al. Immunosuppression by opioids: mechanisms of action on innate and adaptive immunity. Biochemical Pharmacology. 2023:115417.
6 7 8	471 472 473	7. Treede R-D, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, et al. Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11). Pain. 2019;160(1):19- 27.
9 10 11	474 475	8. Sá KN, Moreira L, Baptista AF, Yeng LT, Teixeira MJ, Galhardoni R, et al. Prevalence of chronic pain in developing countries: systematic review and meta-analysis. Pain reports. 2019;4(6).
12 13 14	476 477	<ol> <li>Force CPT. Chronic pain in Canada: Laying a foundation for action: a report by the Canadian Pain Task Force.</li> <li>2019.</li> </ol>
15 16 17	478 479	10. Murray CB, de la Vega R, Murphy LK, Kashikar-Zuck S, Palermo TM. The prevalence of chronic pain in young adults: a systematic review and meta-analysis. Pain. 2022;163(9):e972-e84.
18 19 20	480 481 482	11. Stompór M, Grodzicki T, Stompór T, Wordliczek J, Dubiel M, Kurowska I. Prevalence of chronic pain, particularly with neuropathic component, and its effect on overall functioning of elderly patients. Medical science monitor: international medical journal of experimental and clinical research. 2019;25:2695.
21 22 23	483 484	12. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain—United States, 2022. MMWR Recommendations and Reports. 2022;71(3):1.
24 25 26	485 486	13. Morris SP, Fawcett G, Brisebois L, Hughes J. A demographic, employment and income profile of Canadians with disabilities aged 15 years and over, 2017. Statistics Canada= Statistque Canada; 2018.
27 28	487 488	14. Campbell F, Hudspith M, Choinière M. Working together to better understand, prevent, and manage chronic pain: what we heard. A report by the Canadian Pain Task Force. 2020.
29 30 31	489 490	15. Carriere G, Garner R, Sanmartín C. Significant factors associated with problematic use of opioid pain relief medications among the household population, Canada, 2018. Health Reports. 2021;32(12):11-26.
32 33 34	491 492	16. Ju C, Wei L, Man KK, Wang Z, Ma T-T, Chan AY, et al. Global, regional, and national trends in opioid analgesic consumption from 2015 to 2019: a longitudinal study. The Lancet Public Health. 2022;7(4):e335-e46.
35 36	493 494	17. Kalkman GA, Kramers C, van Dongen RT, van den Brink W, Schellekens A. Trends in use and misuse of opioids in the Netherlands: a retrospective, multi-source database study. The Lancet Public Health. 2019;4(10):e498-e505.
37 38 39	495 496	18. Canada S. Pain relief medication containing opioids, 2018 2018 [Available from: <a href="https://www150.statcan.gc.ca/n1/pub/82-625-x/2019001/article/00008-eng.htm">https://www150.statcan.gc.ca/n1/pub/82-625-x/2019001/article/00008-eng.htm</a> .
40 41 42	497 498	19. Canada Go. Opioid- and Stimulant-related Harms in Canada Published:(June 2023) 2023 [Available from: <a href="https://health-infobase.canada.ca/substance-related-harms/opioids-stimulants/">https://health-infobase.canada.ca/substance-related-harms/opioids-stimulants/</a> .
43 44 45	499 500	20. Geda NR, Janzen B, Pahwa P. Chronic disease multimorbidity among the Canadian population: prevalence and associated lifestyle factors. Archives of Public Health. 2021;79(1):1-11.
46 47	501 502	21. Prego-Domínguez J, Khazaeipour Z, Mallah N, Takkouche B. Socioeconomic status and occurrence of chronic pain: a meta-analysis. Rheumatology. 2021;60(3):1091-105.
48 49 50	503 504	22. Haroutounian S. Postoperative opioids, endocrine changes, and immunosuppression. Pain Reports. 2018;3(2).
51 52 53 54	505 506 507	23. Diasso PD, Birke H, Nielsen SD, Main KM, Højsted J, Sjøgren P, et al. The effects of long-term opioid treatment on the immune system in chronic non-cancer pain patients: A systematic review. European Journal of Pain. 2020;24(3):481-96.
55 56 57	508 509	24. CDC. Trends and Geographic Patterns in Drug and Synthetic Opioid Overdose Deaths — United States, 2013–2019
58		17
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

510 2022.

1 2 3

4

56 57 58

59

60

5 511 25. WHO WHO. Social determinants of health 2023 [Available from: <u>https://www.who.int/health-</u> 6 512 <u>topics/social-determinants-of-health - tab=tab 1</u>.

7
8 513 26. Bennett JM, Reeves G, Billman GE, Sturmberg JP. Inflammation–nature's way to efficiently respond to all
9 514 types of challenges: implications for understanding and managing "the epidemic" of chronic diseases. Frontiers in
10 515 medicine. 2018:316.

516 27. Chapman CR, Tuckett RP, Song CW. Pain and Stress in a Systems Perspective: Reciprocal Neural, Endocrine, and Immune Interactions. YJPAI Journal of Pain. 2008;9(2):122-45.

14 518 28. Slavich GM, Tartter MA, Brennan PA, Hammen C. Endogenous opioid system influences depressive
 15 519 reactions to socially painful targeted rejection life events. Psychoneuroendocrinology. 2014;49:141-9.
 16

1752029.Marchand F, Perretti M, McMahon SB. Role of the immune system in chronic pain. Nature Reviews18521Neuroscience. 2005;6(7):521-32.

19<br/>20<br/>21522<br/>52330.Jiang T, Farkas DK, Ahern TP, Lash TL, Sørensen HT, Gradus JL. Posttraumatic stress disorder and incident<br/>infections: a nationwide cohort study. Epidemiology (Cambridge, Mass). 2019;30(6):911.

524 31. Costa FF, Rosário WR, Farias ACR, de Souza RG, Gondim RSD, Barroso WA. Metabolic syndrome and COVID 525 19: An update on the associated comorbidities and proposed therapies. Diabetes & Metabolic Syndrome: Clinical
 526 Research & Reviews. 2020;14(5):809-14.

527 32. Andersson NW, Goodwin RD, Okkels N, Gustafsson LN, Taha F, Cole SW, et al. Depression and the risk of
 528 severe infections: prospective analyses on a nationwide representative sample. International journal of
 529 epidemiology. 2016;45(1):131-9.

29
 30 530 33. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity
 31 531 and treatment. Rheumatology. 2013;52(1):53-61.

32
 33
 34. Page GG. The immune-suppressive effects of pain. Madame Curie Bioscience Database [Internet]: Landes
 33
 34

534 35. Gowing L, Farrell M, Bornemann R, Ali R. Substitution treatment of injecting opioid users for prevention of
 535 HIV infection. The Cochrane database of systematic reviews. 2004(4):Cd004145.
 37

3853636.Linda G, Michael FF, Reinhard B, Lynn ES, Robert A. Oral substitution treatment of injecting opioid users for39537prevention of HIV infection. Cochrane Database of Systematic Reviews. 2011(8):CD004145.

40
41
42
43
43
43
43
44
4539
4539
4539
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540
4540

541 38. Ronan MV, Herzig SJ. Hospitalizations related to opioid abuse/dependence and associated serious
 542 infections increased sharply, 2002–12. Health Affairs. 2016;35(5):832-7.

4754339.Roy S, Ninkovic J, Banerjee S, Charboneau RG, Das S, Dutta R, et al. Opioid drug abuse and modulation of48544immune function: Consequences in the susceptibility to opportunistic infections. Journal of Neuroimmune49545Pharmacology. 2011;6(4):442-65.

50
 546 40. Roy S, Wang J, Kelschenbach J, Koodie L, Martin J. Modulation of immune function by morphine:
 547 implications for susceptibility to infection. Journal of Neuroimmune Pharmacology. 2006;1(1):77-89.

548 41. Tahamtan A, Tavakoli-Yaraki M, Mokhtari-Azad T, Teymoori-Rad M, Bont L, Shokri F, et al. Opioids and Viral
 549 Infections: A Double-Edged Sword. Front Microbiol Frontiers in Microbiology. 2016;7.

Enseignement Superleur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.	BMJ Open: first published as 10.1136/bmjopen-2023-083791 on 15 October 2024. Downloaded from http://bmjopen.bmj.com/ on June 8, 2025 at Agence Bibliographique de l
---	---

1		
2		
3	550	42. Eisenstein TK. The role of opioid receptors in immune system function. Frontiers in immunology.
4	551	2019;10:2904.
5 6	552	43. Bettinger JJ, Friedman BC. Opioids and Immunosuppression: Clinical Evidence, Mechanisms of Action, and
7	553	Potential Therapies. Palliative Medicine Reports. 2024;5(1):70-80.
8	555	
9	554	44. Kwong JC, Ratnasingham S, Campitelli MA, Daneman N, Deeks SL, Manuel DG, et al. The impact of infection
10	555	on population health: results of the Ontario burden of infectious diseases study. 2012.
11	556	45. Naylor NR, Atun R, Zhu N, Kulasabanathan K, Silva S, Chatterjee A, et al. Estimating the burden of
12	557	antimicrobial resistance: a systematic literature review. Antimicrobial Resistance & Infection Control. 2018;7:1-17.
13	557	
14	558	46. Employees CUoP. Health Care Associated Infections: A Backgrounder: Canadian Union of Public Employees;
15	559	2009.
16	560	47. Kudrina I, Puzhko S, Filion KB, Gore G, Paraskevopoulos E, Windle S, et al. Effectiveness of interventions for
17	561	prevention of common infections in people who use opioids: a protocol for a systematic review of systematic
18	562	reviews. Systematic reviews. 2021;10(1):1-8.
19 20	502	
20	563	48. Puzhko S, Eisenberg MJ, Filion KB, Windle SB, Hébert-Losier A, Gore G, et al. Effectiveness of Interventions
22	564	for Prevention of Common Infections Among Opioid Users: A Systematic Review of Systematic Reviews. Frontiers in
23	565	public health. 2022;10.
24	566	49. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic PainUnited States,
25	567	2016. Jama. 2016;315(15):1624-45.
26	507	
27	568	50. Busse JW, Craigie S, Juurlink DN, Buckley DN, Wang L, Couban RJ, et al. Guideline for opioid therapy and
28	569	chronic noncancer pain. CMAJ : Canadian Medical Association journal = journal de l'Association medicale
29	570	canadienne. 2017;189(18):E659-E66.
30	571	51. Kumar P, Jethwa R, Roycroft G. Chronic pain: supporting safer prescribing of analgesics. British Medical
31	572	Association. 2017.
32		
33 34	573	52. NHS SCCG. Opioid Prescribing for Chronic Pain: Resource Pack. 2022 2022 [Source: nenc-
35	574	sunderland.icb.nhs.uk ]. Available from: <u>https://nenc-sunderland.icb.nhs.uk/wp-</u>
36	575	content/uploads/2023/02/Opioid-resource-pack.pdf?x99445.
37	576	53. Loret A. Usage problématique des traitements opiacés dans l'indication douleur chronique non cancéreuse
38	577	d'origine ostéo-articulaire : Etude descriptive prospective en soins courants [Doctorat]: UNIVERSITÉ DE TOURS; 2022.
39		
40	578	54. Preux C, Bertin M, Tarot A, Authier N, Pinol N, Brugnon D, et al. Prevalence of opioid use disorder among
41	579	patients with cancer-related pain: a systematic review. Journal of Clinical Medicine. 2022;11(6):1594.
42	580	55. Volkow ND, Blanco C. The changing opioid crisis: development, challenges and opportunities. Molecular
43	581	psychiatry. 2021;26(1):218-33.
44 45		
45 46	582	56. Cicero TJ, Ellis MS. The prescription opioid epidemic: a review of qualitative studies on the progression from
46 47	583	initial use to abuse. Dialogues in clinical neuroscience. 2022.
48	584	57. Evans CJ, Cahill CM. Neurobiology of opioid dependence in creating addiction vulnerability. F1000Research.
49	585	2016;5.
50		
51	586	58. Pagé MG, Kudrina I, Zomahoun HTV, Croteau J, Ziegler D, Ngangue P, et al. A systematic review of the
52	587	relative frequency and risk factors for prolonged opioid prescription following surgery and trauma among adults.
53	588	Annals of Surgery. 2020;271(5):845-54.
54	589	59. Ballantyne JC, Sullivan MD. Discovery of endogenous opioid systems: What it has meant for the clinician's
55	590	understanding of pain and its treatment. Pain Pain. 2017;158(12):2290-300.
56 57		
57 58		
58 59		19
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2023-083791 on 15 October 2024. Downloaded from http://bmjopen.bmj.com/ on June 8, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

60. Kosciuczuk U, Knapp P, Lotowska-Cwiklewska AM. Opioid-induced immunosuppression and carcinogenesis promotion theories create the newest trend in acute and chronic pain pharmacotherapy. Clinics. 2020;75. 61. Makman MH, Dvorkin B, Stefano GB. Murine macrophage cell lines contain µ3-opiate receptors. European journal of pharmacology. 1995;273(3):R5-R6. Zhang L, Belkowski JS, Briscoe T, Rogers TJ. Regulation of mu opioid receptor expression in developing T 62. cells. Journal of Neuroimmune Pharmacology. 2012;7:835-42. 63. Raffaeli W, Malafoglia V, Bonci A, Tenti M, Ilari S, Gremigni P, et al. Identification of MOR-positive B cell as possible innovative biomarker (Mu Lympho-Marker) for chronic pain diagnosis in patients with fibromyalgia and osteoarthritis diseases. Int. 2020;21(4):1499. Maher DP, Walia D, Heller NM. Morphine decreases the function of primary human natural killer cells by 64. both TLR4 and opioid receptor signaling. Brain, behavior, and immunity. 2020;83:298-302. 65. Machelska H, Celik MÖ. Opioid receptors in immune and glial cells—implications for pain control. Frontiers in immunology. 2020;11:300. 66. Roeckel L-A, Le Coz G-M, Gavériaux-Ruff C, Simonin F. Opioid-induced hyperalgesia: cellular and molecular mechanisms. Neuroscience. 2016;338:160-82. Franchi S, Moschetti G, Amodeo G, Sacerdote P. Do all opioid drugs share the same immunomodulatory 67. properties? A review from animal and human studies. Frontiers in Immunology. 2019;10:2914. Inagi T, Suzuki M, Osumi M, Bito H. Remifentanil-based anaesthesia increases the incidence of 68. postoperative surgical site infection. Journal of Hospital Infection. 2015;89(1):61-8. 69. Davis MP. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. The journal of supportive oncology. 2012. 70. Manhapra A. Complex Persistent Opioid Dependence—an Opioid-induced Chronic Pain Syndrome. Current treatment options in oncology. 2022:1-15. 71. Daniell HW. Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. The Journal of Pain. 2008;9(1):28-36. 72. Daniell HW. DHEAS deficiency during consumption of sustained-action prescribed opioids: evidence for opioid-induced inhibition of adrenal androgen production. The Journal of Pain. 2006;7(12):901-7. 73. Wiese AD, Griffin MR, Schaffner W, Stein CM, Greevy RA, Mitchel Jr EF, et al. Long-acting opioid use and the risk of serious infections: a retrospective cohort study. Clinical Infectious Diseases. 2019;68(11):1862-9. Sing DC, Barry JJ, Cheah JW, Vail TP, Hansen EN. Long-acting opioid use independently predicts 74. perioperative complication in total joint arthroplasty. The Journal of arthroplasty. 2016;31(9):170-4. e1. 75. Sacerdote P. Opioid-induced immunosuppression. Current opinion in supportive and palliative care. 2008;2(1):14-8. Jacobs R, Karst M, Scheinichen D, Bevilacqua C, Schneider U, Heine J, et al. Effects of fentanyl on cellular 76. immune functions in man. Int J Immunopharmacol. 1999;21(7):445-54. 77. Liu Z, Gao F, Tian Y. Effects of morphine, fentanyl and tramadol on human immune response. Journal of Huazhong University of Science and Technology. 2006;26:478-81. 78. Rodriguez-Vita J, Lawrence T. The resolution of inflammation and cancer. Cytokine & growth factor reviews. 2010;21(1):61-5. 

59

60

1 2		
- 3 4 5	630 631	79. Roy S, Wang J, Kelschenbach J, Koodie L, Martin J. Modulation of immune function by morphine: implications for susceptibility to infection. Journal of Neuroimmune Pharmacology. 2006;1:77-89.
6 7	632 633	80. Sacerdote P, Manfredi B, Mantegazza P, Panerai AE. Antinociceptive and immunosuppressive effects of opiate drugs: a structure-related activity study. British journal of pharmacology. 1997;121(4):834-40.
8 9 10 11	634 635 636	81. Marks LR, Munigala S, Warren DK, Liang SY, Schwarz ES, Durkin MJ. Addiction medicine consultations reduce readmission rates for patients with serious infections from opioid use disorder. Clinical Infectious Diseases. 2019;68(11):1935-7.
12 13 14 15	637 638 639	82. Allen B, Basaraba C, Corbeil T, Rivera BD, Levin FR, Martinez DM, et al. Racial differences in COVID-19 severity associated with history of substance use disorders and overdose: Findings from multi-site electronic health records in New York City. Preventive Medicine. 2023;172:107533.
16 17 18	640 641 642	83. Eidenschink B, Stenzel A, Michael Y, Alwahab U, Kurniali P, Guerrero D. Opioid use prior to admission for chemotherapy induced febrile neutropenia is associated with increased documented infection, sepsis, and death. Journal of Infection and Chemotherapy. 2021;27(4):568-72.
19 20 21 22	643 644 645	84. Tuan W-J, Spotts H, Zgierska AE, Lennon RP. COVID-19 outcomes among adult patients treated with long- term opioid therapy for chronic non-cancer pain in the USA: a retrospective cohort study. BMJ open. 2021;11(11):e056436.
23 24 25 26	646 647 648	85. Oh T-K, Song I-A, Lee J, Eom W, Jeon Y-T. Musculoskeletal disorders, pain medication, and in-hospital mortality among patients with COVID-19 in South Korea: a population-based cohort study. International journal of environmental research and public health. 2021;18(13):6804.
27 28 29 30	649 650 651	86. Alrawashdeh M, Klompas M, Kimmel S, Larochelle MR, Gokhale RH, Dantes RB, et al. Epidemiology, Outcomes, and Trends of Patients With Sepsis and Opioid-Related Hospitalizations in U.S. Hospitals. Critical care medicine. 2021;49(12):2102-11.
31 32	652 653	87. Pirkle S, Reddy S, Bhattacharjee S, Shi LL, Lee MJ. Chronic Opioid Use Is Associated With Surgical Site Infection After Lumbar Fusion. Spine. 2020;45(12):837-42.
33 34 35 36	654 655 656	88. Edelman EJ, Gordon KS, Crothers K, Akgün K, Bryant KJ, Becker WC, et al. Association of Prescribed Opioids With Increased Risk of Community-Acquired Pneumonia Among Patients With and Without HIV. JAMA internal medicine. 2019.
37 38 39 40	657 658 659	89. Oh TK, Song I-A, Lee JH, Lim C, Jeon Y-T, Bae H-J, et al. Preadmission chronic opioid usage and its association with 90-day mortality in critically ill patients: a retrospective cohort study. British journal of anaesthesia. 2019;122(6):e189-e97.
41 42	660 661	90. Khosrow-Khavar F, Kurteva S, Cui Y, Filion KB, Douros A. Opioids and the Risk of Infection: A Critical Appraisal of the Pharmacologic and Clinical Evidence. Expert opinion on drug metabolism & toxicology. 2019;15(7):565-75.
43 44 45	662 663	91. Bell KL, Shohat N, Goswami K, Tan TL, Kalbian I, Parvizi J. Preoperative opioids increase the risk of periprosthetic joint infection after total joint arthroplasty. The Journal of arthroplasty. 2018;33(10):3246-51. e1.
46 47 48 49	664 665 666	92. Zhang R, Meng J, Lian Q, Chen X, Bauman B, Chu H, et al. Prescription opioids are associated with higher mortality in patients diagnosed with sepsis: a retrospective cohort study using electronic health records. PloS one. 2018;13(1):e0190362.
50 51 52	667 668 669	93. Wiese AD, Griffin MR, Schaffner W, Stein CM, Greevy RA, Mitchel EF, Jr., et al. Opioid Analgesic Use and Risk for Invasive Pneumococcal Diseases: A Nested Case-Control Study. Annals of internal medicine. 2018;168(6):396-404.
53	670	04 Colombol LE Sands DE Dutgoarts D. Sandharn W. Danasa S. D'Haans C. at al. The sofaty of yadalisymph for

5467094.Colombel J-F, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'Haens G, et al. The safety of vedolizumab for55671ulcerative colitis and Crohn's disease. Gut. 2017;66(5):839-51.

672 95. Rozell JC, Courtney PM, Dattilo JR, Wu CH, Lee G-C. Preoperative opiate use independently predicts narcotic
 673 consumption and complications after total joint arthroplasty. The Journal of arthroplasty. 2017;32(9):2658-62.

1 2

52

53

59

60

6 674 96. Wiese AD, Griffin MR, Stein CM, Mitchel EF, Grijalva CG. Opioid Analgesics and the Risk of Serious Infections
7 675 Among Patients With Rheumatoid Arthritis: A Self-Controlled Case Series Study. ARTHRITIS & RHEUMATOLOGY.
8 676 2016;68(2):323-31.

9 10 677 97. Li Y, Stocchi L, Cherla D, Liu X, Remzi FH. Association of preoperative narcotic use with postoperative 11 678 complications and prolonged length of hospital stay in patients with Crohn disease. JAMA surgery. 2016;151(8):726-12 679 34.

 13
 14
 14
 15
 16
 98. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, et al. Serious infection and mortality in patients with crohn's disease: More than 5 years of follow-up in the TREAT registry. American Journal of Gastroenterology. 2012;107(9):1409-22.

17 683 99. Dublin S, Walker RL, Jackson ML, Nelson JC, Weiss NS, Korff M, et al. Use of Opioids or Benzodiazepines and
 18 684 Risk of Pneumonia in Older Adults: A Population-Based Case–Control Study. Journal of the American Geriatrics
 19 685 Society. 2011;59(10):1899-907.

686 100. Schwacha MG, McGwin G, Hutchinson CB, Cross JM, MacLennan PA, Rue LW. The contribution of opiate
687 analgesics to the development of infectious complications in burn patients. The American journal of surgery.
688 2006;192(1):82-6.

24<br/>25<br/>26689<br/>690101. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational<br/>studies in epidemiology: a proposal for reporting. Jama. 2000;283(15):2008-12.

691 102. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic
 692 reviews of interventions: John Wiley & Sons; 2019.

30693103.Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for31694systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic reviews. 2015;4(1):1-9.

32
33
695
104. Treede R-D, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, et al. A classification of chronic pain for ICD-11.
696 Pain. 2015;156(6):1003.

35 697 105. Opioid Oral Morphine Milligram Equivalent (MME) Conversion Factors.: Utah University; 2022.
 36

Morgan RL, Whaley P, Thayer KA, Schünemann HJ. Identifying the PECO: a framework for formulating good
 questions to explore the association of environmental and other exposures with health outcomes. Environment
 rot international. 2018;121(Pt 1):1027.

40
 41 701 107. Zalikha Z. Accuracy and acceptability of DeepL Translate in translating legal document: UIN Sunan Gunung
 42 702 Djati Bandung; 2024.

43
 44
 44
 45
 703
 108. Babineau J. Product review: Covidence (systematic review software). Journal of the Canadian Health
 45
 704 Libraries Association/Journal de l'Association des bibliothèques de la santé du Canada. 2014;35(2):68-71.

46 705 109. Cohen J. The effect size. Statistical power analysis for the behavioral sciences. 1988:77-83.

47 48 706 110. McHugh ML. Interrater reliability: the kappa statistic. Biochemia medica. 2012;22(3):276-82.

49
 707 111. Practice CE, Care Oo. EPOC resources for review authors. Cochrane Effective Practice and Organization Care
 708 Oxford (UK); 2017.


709 112. Project EPHP. Quality Assessment Tool for Quantitative Studies. 2023 [Available from: 710 https://www.ephpp.ca/quality-assessment-tool-for-quantitative-studies/.

60

3 4 5	711 712 713	113. Thomas B, Ciliska D, Dobbins M, Micucci S. A process for systematically reviewing the literature: providing the research evidence for public health nursing interventions. Worldviews on Evidence-Based Nursing. 2004;1(3):176-84.
6 7 8 9	714 715 716	114. Armijo-Olivo S, Stiles CR, Hagen NA, Biondo PD, Cummings GG. Assessment of study quality for systematic reviews: a comparison of the Cochrane Collaboration Risk of Bias Tool and the Effective Public Health Practice Project Quality Assessment Tool: methodological research. Journal of evaluation in clinical practice. 2012;18(1):12-8.
10 11 12 13	717 718 719	115. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Journal of clinical epidemiology. 2009;62(10):e1-e34.
14 15 16	720 721	116. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. bmj. 2021;372.
17 18	722 723	117. Cochrane. ReviewManager (RevMan) is Cochrane's bespoke software for writing Cochrane Reviews. 2020 [Available from: <u>https://training.cochrane.org/online-learning/core-software/revman</u> .
19 20 21	724 725	118. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in medicine. 2002;21(11):1539-58.
22 23 24	726 727	119. Deeks JJ, Higgins JP, Altman DG, Group CSM. Analysing data and undertaking meta-analyses. Cochrane handbook for systematic reviews of interventions. 2019:241-84.
25 26 27	728 729	120. Borenstein M, Higgins JP, Hedges LV, Rothstein HR. Basics of meta-analysis: I2 is not an absolute measure of heterogeneity. Research synthesis methods. 2017;8(1):5-18.
28 29	730 731	121. IntHout J, Ioannidis JP, Rovers MM, Goeman JJ. Plea for routinely presenting prediction intervals in meta- analysis. BMJ open. 2016;6(7):e010247.
30 31 32	732 733	122. Thota RS, Ramkiran S, Garg R, Goswami J, Baxi V, Thomas M. Opioid free onco-anesthesia: Is it time to convict opioids? A systematic review of literature. Journal of anaesthesiology, clinical pharmacology. 2019;35(4):441.
33 34 35	734 735	123. Toleska M, Dimitrovski A. Is opioid-free general anesthesia more superior for postoperative pain versus opioid general anesthesia in laparoscopic cholecystectomy? prilozi. 2019;40(2):81-7.
36 37	736 737	124. Salas J, Scherrer JF, Schneider FD, Sullivan MD, Bucholz KK, Burroughs T, et al. New-onset depression following stable, slow, and rapid rate of prescription opioid dose escalation. Pain. 2017;158(2):306-12.
38 39	738	125. Scherrer J. New-onset depression linked to prolonged opioid use, not dose. Reactions. 2016;1586:11-30.
40 41 42	739 740	126. Jensen MK, Thomsen AB, Hojsted J. 10-year follow-up of chronic non-malignant pain patients: Opioid use, health related quality of life and health care utilization. European Journal of Pain. 2006;10(5):423-33.
43 44	741 742	127. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain medicine. 2005;6(6):432-42.
45 46 47	743 744	128. Guyatt GH, Oxman AD, Schünemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. Journal of clinical epidemiology. 2011;64(4):380-2.
48 49	745	
50 51	746	
52	747	
53 54	748	
55 56	749	
57		
58 59		23
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2023-083791 on 15 October 2024. Downloaded from http://bmjopen.bmj.com/ on June 8, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

1 2 3 4 5 6 7 8 9	750 751 752 753	<b>Figure 1</b> . Direct acyclic graph (DAG) for the association between opioid use and infectious complications among patients with chronic pain.
10 11 12 13 14 15 16 17 18 19 20 21 22		
23 24 25 26 27 28 29 30 31 32 33 34 35		
35 36 37 38 39 40 41 42 43 44 45 46 47		
48 49 50 51 52 53 54 55 56 57 58 59 60		24 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml



BMJ Open: first published as 10.1136/bmjopen-2023-083791 on 15 October 2024. Downloaded from http://bmjopen.bmj.com/ on June 8, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) .

Protected by copyright, including for uses related

# Reporting checklist for protocol of a systematic review and meta analysis.

Based on the PRISMA-P guidelines.

# Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-Preporting guidelines, and cite them as:

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.

Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 Syst Rev. 2015;4(1):1.			
			Page
		Reporting Item	Number
Title			
Identification	<u>#1a</u>	Identify the report as a protocol of a systematic review	1
Update	<u>#1b</u>	If the protocol is for an update of a previous systematic	N/A
	For pe	review, identify as such er review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2 3	Registration			
4 5		<u>#2</u>	If registered, provide the name of the registry (such as	5
6 7 8			PROSPERO) and registration number	
9 10 11 12	Authors			
12 13 14	Contact	<u>#3a</u>	Provide name, institutional affiliation, e-mail address of all	1
15 16			protocol authors; provide physical mailing address of	
17 18 19			corresponding author	
20 21	Contribution	<u>#3b</u>	Describe contributions of protocol authors and identify the	13
22 23 24			guarantor of the review	
24 25 26	Amendments			
27 28				
29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46		<u>#4</u>	If the protocol represents an amendment of a previously	6
			completed or published protocol, identify as such and list	
			changes; otherwise, state plan for documenting important	
			protocol amendments	
	Support			
	Cupport			
	Sources	<u>#5a</u>	Indicate sources of financial or other support for the review	13
	Sponsor	<u>#5b</u>	Provide name for the review funder and / or sponsor	N/A
47 48 49	Role of sponsor or	<u>#5c</u>	Describe roles of funder(s), sponsor(s), and / or institution(s),	N/A
50 51 52 53 54 55	funder		if any, in developing the protocol	
	Introduction			
56 57 58	Rationale	<u>#6</u>	Describe the rationale for the review in the context of what is	2
59 60		For pee	er review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2			already known	
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Objectives	<u>#7</u>	Provide an explicit statement of the question(s) the review will	5
			address with reference to participants, interventions,	
			comparators, and outcomes (PICO)	
	Methods			
	Eligibility criteria	<u>#8</u>	Specify the study characteristics (such as PICO, study design,	7
			setting, time frame) and report characteristics (such as years	
18 19 20			considered, language, publication status) to be used as	
20 21 22			criteria for eligibility for the review	
22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40	Information	#9	Describe all intended information sources (such as electronic	7
	sources	<u></u>	databases, contact with study authors, trial registers or other	,
	3001003		grey literature sources) with planned dates of coverage	
			grey incrature sources) with planned dates of coverage	
	Search strategy	<u>#10</u>	Present draft of search strategy to be used for at least one	7
			electronic database, including planned limits, such that it	
			could be repeated	
	Study records -	<u>#11a</u>	Describe the mechanism(s) that will be used to manage	8
41 42	data management		records and data throughout the review	
43 44 45	Study records -	<u>#11b</u>	State the process that will be used for selecting studies (such	8
46 47	selection process	<u>#110</u>	as two independent reviewers) through each phase of the	0
48 49	selection process		review (that is, screening, eligibility and inclusion in meta-	
50 51				
52 53 54			analysis)	
54 55 56	Study records -	<u>#11c</u>	Describe planned method of extracting data from reports	9
57 58	data collection		(such as piloting forms, done independently, in duplicate), any	
59 60		For pee	er review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29	process		processes for obtaining and confirming data from investigators	
	Data items	<u>#12</u>	List and define all variables for which data will be sought	9
			(such as PICO items, funding sources), any pre-planned data	
			assumptions and simplifications	
	Outcomes and	<u>#13</u>	List and define all outcomes for which data will be sought,	9
	prioritization		including prioritization of main and additional outcomes, with	
			rationale	
	Risk of bias in	#14	Describe anticipated methods for assessing risk of bias of	10
		<u>#14</u>		10
	individual studies		individual studies, including whether this will be done at the	
			outcome or study level, or both; state how this information will	
			be used in data synthesis	
	Data synthesis	#15a	Describe criteria under which study data will be quantitatively	10
30 31	5		synthesised	
32 33			Synthesised	
34 35	Data synthesis	<u>#15b</u>	If data are appropriate for quantitative synthesis, describe	
36 37			planned summary measures, methods of handling data and	
38 39			methods of combining data from studies, including any	
40 41			planned exploration of consistency (such as I2, Kendall's τ)	
42 43				
44 45	Data synthesis	<u>#15c</u>	Describe any proposed additional analyses (such as	11
46 47 48 49			sensitivity or subgroup analyses, meta-regression)	
	Data synthesis	#15d	If quantitative synthesis is not appropriate, describe the type	12
50 51	<b>,</b>		of summary planned	
52 53 54 55 56 57 58				
	Meta-bias(es)	<u>#16</u>	Specify any planned assessment of meta-bias(es) (such as	12
			publication bias across studies, selective reporting within	
59 60		For pee	er review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	
		-		

1 2			studies)	ВМЈ Оре				
2 3 4	Confidence in	<u>#17</u>	Describe how the strength of the body of evidence will be	n: firs				
5 6	cumulative		assessed (such as GRADE)	t publi				
7 8 9	evidence			shed a				
10 11 12	studies)       Confidence in #17       Describe how the strength of the body of evidence will be 12       12         cumulative       assessed (such as GRADE)       evidence       12         None The PRISMA-P elaboration and explanation paper is distributed under the terms of the Creative Commons Attribution Licerse CC-BY. This checklist can be completed online using       https://www.goodreports.org/, a tool made by the EQUATOR Network in collaboration with       Penelope.ai       Penelope.ai							
13 14	Commons Attribution License CC-BY. This checklist can be completed online using							
15 16	https://www.goodreports.org/, a tool made by the EQUATOR Network in collaboration with							
17 18 19	Penelope.ai			23-083 ght, in				
20 21				cludin				
22 23				on 15 Ou ling for u				
24 25				October 2024. Downloaded Enseignement Superieur r uses related to text and d				
26 27				- 2024. Do gnement slated to				
28 29				ont Surto tex				
30 31				hloade perieu t and c				
32 33 34				data m data m				
35 36				n http: ES) - vining,				
37 38								
39 40				/bmjopen.bmj.com/ on June 8, 2025 ; Al training, and similar technologies				
41 42				and s				
43 44				similar				
45 46				June r techi				
47 48				8, 202 nologi				
49 50				les.				
51 52				lgenc				
53 54				e Bibl				
55 56				iogra				
57 58				/bmjopen.bmj.com/ on June 8, 2025 at Agence Bibliographique de l Al training, and similar technologies.				
59 60		For pe	er review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	e de l				